

MEDTRONIC INC
Form 10-Q
March 04, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q

x **QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 23, 2009**

Commission File Number 1-7707

MEDTRONIC, INC.

(Exact name of registrant as specified in its charter)

Minnesota
(State of incorporation)

41-0793183
(I.R.S. Employer
Identification No.)

710 Medtronic Parkway
Minneapolis, Minnesota 55432
(Address of principal executive offices) (Zip Code)

(763) 514-4000
(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

Shares of common stock, \$.10 par value, outstanding on February 27, 2009: 1,119,284,090

TABLE OF CONTENTS

Item	Description	Page
	<u>PART I</u>	
1.	<u>Financial Statements</u>	1
2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	29
3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	50
4.	<u>Controls and Procedures</u>	51
	<u>PART II</u>	
1.	<u>Legal Proceedings</u>	51
2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	52
6.	<u>Exhibits</u>	53

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

MEDTRONIC, INC.
 CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
 (Unaudited)

	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
	(in millions, except per share data)			
Net sales	\$ 3,494	\$ 3,405	\$ 10,770	\$ 9,655
Costs and expenses:				
Cost of products sold	848	870	2,586	2,502
Research and development expense	337	329	987	927
Selling, general and administrative expense	1,257	1,207	3,838	3,410
Special charges		78		78
Restructuring charges			96	14
Certain litigation charges		366	266	366
Purchased in-process research and development (IPR&D) charges	72	310	90	343
Other expense, net	50	119	344	248
Interest (income)/expense, net	(2)	(9)	17	(114)
Total costs and expenses	2,562	3,270	8,224	7,774
Earnings before income taxes	932	135	2,546	1,881
Provision for income taxes	209	58	505	463
Net earnings	\$ 723	\$ 77	\$ 2,041	\$ 1,418
Earnings per share:				
Basic	\$ 0.65	\$ 0.07	\$ 1.82	\$ 1.25
Diluted	\$ 0.65	\$ 0.07	\$ 1.81	\$ 1.24
Weighted average shares outstanding:				
Basic	1,115.0	1,126.9	1,118.7	1,132.9
Diluted	1,119.5	1,135.0	1,125.6	1,145.3
Cash dividends declared per common share	\$ 0.188	\$ 0.125	\$ 0.563	\$ 0.375

The accompanying notes are an integral part of these consolidated financial statements.

Edgar Filing: MEDTRONIC INC - Form 10-Q

MEDTRONIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	January 23, 2009	April 25, 2008
	(in millions, except per share data)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,283	\$ 1,060
Short-term investments	460	553
Accounts receivable, less allowances of \$60 and \$99, respectively	2,954	3,287
Income tax receivable	50	73
Inventories	1,429	1,280
Deferred tax assets, net	368	600
Prepaid expenses and other current assets	662	469
Total current assets	7,206	7,322
Property, plant and equipment	4,804	4,743
Accumulated depreciation	(2,548)	(2,522)
Property, plant and equipment, net	2,256	2,221
Goodwill	7,744	7,519
Other intangible assets, net	2,186	2,193
Long-term investments	2,641	2,322
Long-term deferred tax assets, net	54	103
Other assets	677	518
Total assets	\$ 22,764	\$ 22,198
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Short-term borrowings	\$ 1,184	\$ 1,154
Accounts payable	363	383
Accrued compensation	745	789
Other accrued expenses	876	1,209
Total current liabilities	3,168	3,535
Long-term debt	5,525	5,802
Long-term accrued compensation and retirement benefits	303	304
Long-term accrued income taxes	571	519
Other long-term liabilities	133	502
Total liabilities	9,700	10,662
Commitments and contingencies (Note 18)		
Shareholders' equity:		
Preferred stock - par value \$1.00		
Common stock - par value \$0.10	112	112
Retained earnings	12,987	11,710
Accumulated other comprehensive loss	(35)	(286)
Total shareholders' equity	13,064	11,536
Total liabilities and shareholders' equity	\$ 22,764	\$ 22,198

The accompanying notes are an integral part of these consolidated financial statements.

Edgar Filing: MEDTRONIC INC - Form 10-Q

MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Nine months ended	
	January 23, 2009	January 25, 2008
	(in millions)	
Operating Activities:		
Net earnings	\$ 2,041	\$ 1,418
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	522	457
Special charges		78
IPR&D charges	90	343
Provision for doubtful accounts	31	23
Deferred income taxes	103	(144)
Stock-based compensation	178	163
Excess tax benefit from exercise of stock-based awards	(23)	(32)
Change in operating assets and liabilities, net of effect of acquisitions:		
Accounts receivable	252	(159)
Inventories	(230)	(17)
Accounts payable and accrued liabilities	(51)	320
Other operating assets and liabilities	(158)	450
Net cash provided by operating activities	2,755	2,900
Investing Activities:		
Acquisitions, net of cash acquired	(381)	(4,179)
Purchase of intellectual property	(152)	(88)
Additions to property, plant and equipment	(378)	(423)
Purchases of marketable securities	(2,246)	(5,759)
Sales and maturities of marketable securities	2,182	7,991
Other investing activities, net	(270)	(228)
Net cash used in investing activities	(1,245)	(2,686)
Financing Activities:		
Change in short-term borrowings, net	41	707
Issuance of long-term debt		300
Payments on long-term debt	(316)	(172)
Dividends to shareholders	(632)	(425)
Issuance of common stock	393	326
Excess tax benefit from exercise of stock-based awards	23	32
Repurchase of common stock	(726)	(1,464)
Net cash used in financing activities	(1,217)	(696)
Effect of exchange rate changes on cash and cash equivalents	(70)	(45)
Net change in cash and cash equivalents	223	(527)
Cash and cash equivalents at beginning of period	1,060	1,256
Cash and cash equivalents at end of period	\$ 1,283	\$ 729
Supplemental Cash Flow Information		
Cash Paid For:		
Income taxes	\$ 367	\$ 427
Interest	136	168
Supplemental Noncash Investing and Financing Activities:		
Reclassification of debentures from short-term to long-term debt	\$ 15	\$
Reclassification of debentures from long-term to short-term debt		94

Edgar Filing: MEDTRONIC INC - Form 10-Q

The accompanying notes are an integral part of these consolidated financial statements.

Edgar Filing: MEDTRONIC INC - Form 10-Q

MEDTRONIC, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Dollars in millions, except per share data

Note 1 Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Medtronic, Inc. and its subsidiaries (Medtronic or the Company) for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended April 25, 2008.

The Company's fiscal years 2009, 2008 and 2007 will end or ended on April 24, 2009, April 25, 2008 and April 27, 2007, respectively.

Note 2 New Accounting Pronouncements

Effective April 26, 2008, the Company adopted Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements (SFAS No. 157). SFAS No. 157 establishes a framework for measuring fair value in accordance with generally accepted accounting principles, clarifies the definition of fair value within that framework and expands disclosures about fair value measurements. SFAS No. 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, except for the measurement of share-based payments. SFAS No. 157 does not expand the use of fair value in any new circumstances. For certain types of financial instruments, SFAS No. 157 requires a limited form of retrospective transition, whereby the cumulative impact of the change in principle is recognized in the opening balance in retained earnings in the fiscal year of adoption. All other provisions of SFAS No. 157 will be applied prospectively. On February 12, 2008, the FASB issued FASB Staff Position (FSP) FAS 157-2, Effective Date of FASB Statement No. 157 (FSP FAS No. 157-2). FSP FAS No. 157-2 defers the implementation of SFAS No. 157 for certain nonfinancial assets and nonfinancial liabilities. Accordingly, the Company adopted the required provisions of SFAS No. 157 at the beginning of fiscal year 2009 and the remaining provisions will be adopted by the Company at the beginning of fiscal year 2010. The fiscal year 2009 adoption did not result in a material impact to the Company's financial statements (see Note 7). The Company is currently evaluating the impact of adopting the remaining parts of SFAS No. 157 in fiscal year 2010 in accordance with FSP FAS No. 157-2.

In September 2006, the FASB issued SFAS No. 158, Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans—an amendment of FASB Statements No. 87, 88, 106 and 132(R) (SFAS No. 158), which requires the recognition of an asset or liability for the funded status of defined benefit pension and other post-retirement benefit plans in the statement of financial position. The funded status recognition and certain disclosure provisions of SFAS No. 158 were adopted for the Company's fiscal year ended April 25, 2008. See Notes 1 and 13 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 25, 2008 for the impact of this adoption. SFAS No. 158 also requires the consistent measurement of plan assets and benefit obligations as of the date of the Company's fiscal year-end statement of financial position effective for the Company's fiscal year ending April 24, 2009. A select number of the Company's plans, including the U.S. plans, currently have a January 31 measurement date. This standard will require the Company to change that measurement date to match the date of the Company's fiscal year-end in fiscal year 2009. The Company will adopt the new measurement date provisions of SFAS No. 158 in the fourth quarter of fiscal year 2009 which will result in a one-time adjustment to retained earnings and accumulated other comprehensive income in that period.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations (SFAS No. 141(R)). SFAS No. 141(R) replaces SFAS No. 141, Business Combinations. SFAS No. 141(R) establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interests in the acquiree and the goodwill acquired. Some of the key changes under SFAS No. 141(R) will impact the accounting treatment for certain acquisition related items including: (1) accounting for acquired in process research and development (IPR&D) as an indefinite-lived intangible asset until approved or discontinued rather than as an immediate expense; (2) expensing acquisition costs rather than adding them to the cost of an acquisition; (3) expensing restructuring costs in connection with an acquisition rather than adding them to the cost of an acquisition; (4) including the fair value of contingent consideration at the date of an acquisition in the cost of an acquisition; and (5) recording at the date of an acquisition the fair value of contingent liabilities that are more likely than not to occur. SFAS No. 141(R) also includes a substantial number of new disclosure requirements. SFAS No. 141(R) will be effective for the Company beginning fiscal year 2010 and must be applied prospectively to all new acquisitions closing on or after April 25,

Edgar Filing: MEDTRONIC INC - Form 10-Q

2009. Early adoption of SFAS No. 141(R) is prohibited. SFAS No. 141(R) is expected to have a material impact on how the Company will identify, negotiate, and value future acquisitions and a material impact on how an acquisition will affect the Company's consolidated financial statements.

Edgar Filing: MEDTRONIC INC - Form 10-Q

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51 (SFAS No. 160). SFAS No. 160 will change the accounting and reporting for minority interests, which will be recharacterized as noncontrolling interests and classified as a component of equity as compared to a liability today. This new consolidation method will significantly change the accounting for partial and/or step acquisitions. SFAS No. 160 will be effective for the Company in the first quarter of fiscal year 2010. The Company does not believe the adoption of SFAS No. 160 will have a material impact to the Company's consolidated financial statements.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities (SFAS No. 161), which will require increased disclosures about an entity's strategies and objectives for using derivative instruments; the location and amounts of derivative instruments in an entity's financial statements; how derivative instruments and related hedged items are accounted for under SFAS No. 133, Accounting for Derivative and Hedging Activities (SFAS No. 133); and how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. Certain disclosures will also be required with respect to derivative features that are credit risk-related. SFAS No. 161 is effective for the Company beginning in the fourth quarter of fiscal year 2009 but only requires the revised disclosures on a prospective basis. The Company will provide the additional disclosures necessary to the consolidated financial statements beginning in the Company's fourth quarter of fiscal year 2009.

In May 2008, the FASB issued FSP APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (FSP APB 14-1). FSP APB 14-1 requires the proceeds from the issuance of such convertible debt instruments to be allocated between a liability component (issued at a discount) and an equity component. The resulting debt discount is amortized over the period the convertible debt is expected to be outstanding as additional non-cash interest expense. The change in accounting treatment is effective for the Company beginning in fiscal year 2010, and will be applied retrospectively to prior periods. FSP APB 14-1 changes the accounting treatment for the Company's \$2,200 of 1.500 percent and \$2,200 of 1.625 percent Senior Convertible Notes due in 2011 and 2013, respectively, which were issued in April 2006, and the \$15 remaining balance of the Company's Contingent Convertible Debentures due 2021. Based on the Company's preliminary evaluation, upon adoption of FSP APB 14-1 in fiscal year 2010, the convertible debt liability will decrease by approximately \$520 and 2009 and 2010 interest expense for the convertible debt will increase by approximately \$154 and \$167, respectively. Using diluted weighted average shares outstanding for the nine months ended January 23, 2009, the Company estimates the impact to diluted earnings per share as a decrease of \$0.09 and \$0.10 for fiscal year 2009 and 2010, respectively.

In June 2008, the FASB issued FSP Emerging Issues Task Force (EITF) Issue No. 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities (FSP EITF No. 03-6-1). FSP EITF No. 03-6-1 provides that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of EPS pursuant to the two-class method. FSP EITF No. 03-6-1 is effective for the Company beginning in the first quarter of fiscal year 2010. Upon adoption, all prior-period EPS data is required to be adjusted retrospectively (including interim financial statements, summaries of earnings, and selected financial data) to conform with the provisions of FSP EITF No. 03-6-1. FSP EITF No. 03-6-1 is applicable to the Company and the Company is currently evaluating the impact that FSP EITF No. 03-6-1 will have on the consolidated financial statements.

In November 2008, the FASB ratified EITF Issue No. 08-6, Equity Method Investment Accounting Considerations (EITF No. 08-6). EITF No. 08-6 applies to all investments accounted for under the equity method and clarifies the accounting for certain transactions and impairment considerations involving equity method investments. EITF No. 08-6 is effective for the Company beginning in the first quarter of fiscal year 2010. The Company is currently evaluating the impact that EITF No. 08-6 will have on the consolidated financial statements.

In November 2008, the FASB ratified EITF Issue No. 08-7, Accounting for Defensive Intangible Assets (EITF No. 08-7). EITF No. 08-7 applies to defensive intangible assets, which are acquired intangible assets that an entity does not intend to actively use but does intend to prevent others from obtaining access to the asset. EITF No. 08-7 requires an entity to account for defensive intangible assets as a separate unit of accounting. Defensive intangible assets should not be included as part of the cost of an entity's existing intangible assets because the defensive intangible assets are separately identifiable. Defensive intangible assets must be recognized at fair value in accordance with SFAS No. 141(R) and SFAS No. 157. EITF No. 08-7 is effective for intangible assets acquired by the Company on or after April 25, 2009. The Company is currently evaluating the impact that EITF No. 08-7 will have on the consolidated financial statements.

Edgar Filing: MEDTRONIC INC - Form 10-Q

In December 2008, the FASB issued FSP SFAS No. 132(R)-1, *Employers' Disclosures About Postretirement Benefit Plan Assets* (FSP SFAS No. 132(R)-1). FSP SFAS No. 132(R)-1 requires increased disclosures about an entity's postretirement benefit plan assets. Specifically, FSP SFAS No. 132(R)-1 requires an entity to disclose information regarding its investment policies and strategies, its categories of plan assets, its fair value measurements of plan assets, and any significant concentrations of risk in plan assets. FSP SFAS No. 132(R)-1 is effective for the Company beginning in the first quarter of fiscal year 2010 but only requires the revised disclosures on a prospective basis. The Company will provide the additional disclosures necessary to the consolidated financial statements beginning in the Company's fourth quarter of fiscal year 2010.

Note 3 Acquisitions and IPR&D Charges

When the Company acquires another company or a group of assets, the purchase price is allocated, as applicable, between IPR&D, other identifiable intangible assets, net tangible assets, and goodwill as required by U.S. GAAP. Goodwill represents the excess of the aggregate purchase price over the fair value of net assets, including IPR&D, of acquired businesses. The values assigned to IPR&D and other identifiable intangible assets are based on valuations that have been prepared using methodologies and valuation techniques consistent with those used by independent appraisers. These techniques include estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values utilizing an appropriate risk-adjusted rate of return (discount rate). The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. For IPR&D, these methodologies include consideration of the risk of the project not achieving commercial feasibility and include a factor that takes into account the uncertainty surrounding the successful development of the IPR&D.

At the time of acquisition, the Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that the commercial viability of these products will actually be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, and conducting clinical trials necessary to obtain regulatory approvals. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, and patent issuance, validity and litigation, if any. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these therapies.

Fiscal Year 2009

CryoCath Technologies Inc.

On November 12, 2008, the Company acquired substantially all of the shares of CryoCath Technologies Inc. (CryoCath). Under the terms of the agreement announced on September 25, 2008, CryoCath shareholders received \$8.75 Canadian dollars per share in cash for each share of CryoCath common stock that they owned. Total consideration for the transaction, net of cash acquired, was approximately \$352 U.S. dollars including the purchase of all outstanding CryoCath common stock, the assumption and settlement of existing CryoCath debt and payment of direct acquisition costs. CryoCath develops cryotherapy products to treat cardiac arrhythmias. CryoCath's Arctic Front product is a minimally invasive cryo-balloon catheter designed specifically to treat atrial fibrillation and is currently approved in certain markets outside the U.S.

The Company has accounted for the acquisition of CryoCath as a business combination under U.S. GAAP. Under business combination accounting, the assets and liabilities of CryoCath were recorded as of the acquisition date, at their respective fair values, and consolidated with the Company. The purchase price allocation is based on estimates of the fair value of assets acquired and liabilities assumed. The preliminary purchase price has been allocated as follows:

Current assets	\$	23
Property, plant and equipment		2
IPR&D		72
Other intangible assets		57
Goodwill		227
Deferred tax assets, long-term		14
Total assets acquired		395
Current liabilities		25
Deferred tax liabilities, long-term		15
Total liabilities assumed		40
Net assets acquired	\$	355

Edgar Filing: MEDTRONIC INC - Form 10-Q

In connection with the acquisition of CryoCath, the Company acquired \$57 of technology-based intangible assets with an estimated useful life of 11 years. Also as part of the acquisition, the Company recognized, in total, \$72 and \$227 of IPR&D and goodwill, respectively. The IPR&D was expensed on the date of acquisition and primarily relates to the future launch of Arctic Front into the U.S. market. Various factors contributed to the establishment of goodwill, including the value of CryoCath's highly trained assembled workforce, and the expected revenue growth that is attributable to increased market penetration from future products and customers. The goodwill is not deductible for tax purposes.

Restore Medical Acquisition

On July 16, 2008, the Company acquired Restore Medical, Inc. (Restore). Restore's Pillar Palatal Implant System (Pillar System) will be integrated into the Surgical Technologies operating segment of the Company. The Pillar System will provide the Company with a minimally invasive, implantable medical device used to treat the soft palate component of sleep breathing disorders, including mild to moderate obstructive sleep apnea and snoring. Restore shareholders received \$1.60 per share in cash for each share of Restore common stock they owned. Total consideration for the transaction was approximately \$29, net of cash acquired.

In connection with the acquisition of Restore, the Company acquired \$17 of technology-based intangible assets with an estimated useful life of 10 years, \$8 of net tangible assets, and \$5 of goodwill. The goodwill is not deductible for tax purposes.

The pro forma impact of the CryoCath and Restore acquisitions was not significant, individually or in the aggregate, to the results of the Company for the three and nine months ended January 23, 2009 or January 25, 2008. The results of operations related to each company have been included in the Company's consolidated statements of earnings since the date each company was acquired.

Fiscal Year 2008

Kyphon Acquisition

On November 2, 2007, the Company acquired Kyphon Inc. (Kyphon) and it became a wholly owned subsidiary of the Company. Kyphon develops and markets medical devices designed to restore and preserve spinal function using minimally invasive technology. Kyphon's primary products are used in balloon kyphoplasty for the treatment of spinal compression fractures caused by osteoporosis or cancer, and in the interspinous process decompression procedure for treating the symptoms of lumbar spinal stenosis. It is expected that the acquisition of Kyphon will add to the growth of the Company's existing Spinal business by extending its product offerings and enabling the Company to provide physicians with a broader range of therapies for use at all stages of the care continuum.

Under the terms of the agreement announced on July 27, 2007, Kyphon shareholders received \$71 per share in cash for each share of Kyphon common stock they owned. Total consideration for the transaction was approximately \$4,203, which includes payments to Kyphon shareholders for the cancellation of outstanding shares, the assumption and settlement of existing Kyphon debt and payment of direct acquisition costs. Total debt assumed relates to Kyphon's obligations under existing credit and term loan facilities and outstanding senior convertible notes. In addition, the total consideration includes the proceeds of unwinding the related convertible note hedges and cancellation and payment of the warrants to the hedge participants that were originally issued by Kyphon in February 2007. The transaction was financed through a combination of approximately \$3,303 cash on hand, the issuance of \$600 short-term commercial paper and borrowing \$300 through a new long-term unsecured revolving credit facility.

The Company has accounted for the acquisition of Kyphon as a business combination under U.S. GAAP. Under business combination accounting, the assets and liabilities of Kyphon were recorded as of the acquisition date, at their respective fair values, and consolidated with the Company. The break down of the purchase price of Kyphon is as follows:

Cash acquisition of Kyphon outstanding common stock	\$	3,300
Cash settlement of vested stock-based awards		218
Debt assumed and settled		570
Cash settlement of convertible debt warrants, net of proceeds from convertible note hedges		87
Direct acquisition costs		28
Total purchase price	\$	4,203

Edgar Filing: MEDTRONIC INC - Form 10-Q

The purchase price allocation is based on estimates of the fair value of assets acquired and liabilities assumed. The purchase price has been allocated as follows:

Current assets	\$	367
Property, plant and equipment		39
IPR&D		290
Other intangible assets		996
Goodwill		3,177
Other long-term assets		10
Total assets acquired		4,879
Current liabilities		361
Deferred tax liabilities		282
Other long-term liabilities		33
Total liabilities assumed		676
Net assets acquired	\$	4,203

In connection with the acquisition, the Company acquired \$996 of intangible assets that had a weighted average useful life of approximately 10.5 years. The intangible assets include \$887 of technology-based assets and \$109 of tradenames with weighted average lives of 10.5 years and 11 years, respectively. Also as part of the acquisition, the Company recognized, in total, \$290 and \$3,177 for IPR&D and goodwill, respectively. The IPR&D was expensed on the date of acquisition. Various factors contributed to the establishment of goodwill, including: the benefit of adding existing products of the Company to the portfolio of products already sold by Kyphon sales representatives; the value of Kyphon's highly trained assembled workforce; and the expected revenue growth that is attributable to expanded indications and increased market penetration from future products and customers. The goodwill is not deductible for tax purposes.

The \$290 IPR&D charge primarily relates to three projects: 1) future launch of the balloon kyphoplasty (kyphoplasty) procedure into the Japanese market, 2) future launch of the Aperius product into the U.S. market, and 3) the development of the next generation kyphoplasty balloon technology. Kyphoplasty is Kyphon's minimally invasive approach to treat spinal fractures including vertebral compression fractures due to osteoporosis and cancer. Aperius is Kyphon's internally developed interspinous spacing device which provides a minimally invasive approach to treat lumbar spinal stenosis. For purposes of valuing the acquired IPR&D, the Company estimated total costs to complete of approximately \$19.

As required, the Company recognized a \$34 fair value adjustment related to inventory acquired from Kyphon. Inventory fair value is defined as the estimated selling price less the sum of (a) cost to complete (b) direct costs to sell and (c) a reasonable profit allowance for the selling effort. The \$34 fair value adjustment was fully expensed through cost of products sold during the third quarter of fiscal year 2008, which reflects the estimated period over which the acquired inventory was sold to customers.

In connection with the acquisition, the Company began to assess and formulate a plan for the elimination of duplicative positions, employee relocations, the exit of certain facilities, and the termination of certain contractual obligations. The purchase accounting liabilities recorded in connection with these activities were approximately \$68 and included approximately \$48 for termination benefits and employee relocation and approximately \$20 of estimated costs to cancel contractual obligations. The remaining balance of these liabilities as of January 23, 2009 was approximately \$18. The Company continues to assess these liabilities and until the integration activities are complete, the allocation of the purchase price is subject to adjustment.

The Company's condensed consolidated financial statements include Kyphon's operating results from the date of acquisition, November 2, 2007. The following unaudited pro forma information sets forth the combined results of Medtronic's and Kyphon's operations for the nine months ended January 25, 2008 as if the acquisition had occurred at the beginning of the period presented. The unaudited pro forma results of operations for the nine month period ended January 25, 2008 is comprised of (i) Kyphon's historical financial information for the six months ended September 30, 2007, (ii) Medtronic's historical financial information for the six months ended October 27, 2007 and (iii) the Company's actual results for the three months ended January 25, 2008.

The pro forma information gives effect to actual combined operating results of the Company and Kyphon prior to the acquisition, adjusted to reflect, among other things, reduced interest income, additional intangible asset amortization and interest expense that would have resulted from the change in the accounting basis of certain assets and liabilities due to the acquisition. Pro forma adjustments are tax-effected at the Company's statutory tax rate. No effect has been given to cost reductions or operating synergies in this presentation. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred as of the beginning of the periods presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings. The unaudited pro forma condensed consolidated financial information is presented for informational purposes only.

	Nine months ended January 25, 2008
(dollars in millions, except per share data)	
Net sales	\$ 9,944
Net earnings	\$ 1,281
Earnings per share:	
Basic	\$ 1.13
Diluted	\$ 1.13

The unaudited pro forma financial information for the nine months ended January 25, 2008 includes a \$290 IPR&D charge and a \$34 increase in cost of products sold related to the step-up to fair value of inventory acquired, both of which are non-recurring.

Other Acquisitions and IPR&D Charges

During the second quarter of fiscal year 2009, the Company recorded an IPR&D charge of \$18 related to the purchase of certain intellectual property for use in the Spinal business. These payments were expensed as IPR&D since technological feasibility of the underlying product had not yet been reached and such technology has no future alternative use.

On November 1, 2007, the Company recorded an IPR&D charge of \$20 related to the acquisition of Setagon, Inc. (Setagon), a development stage company focused on commercially developing metallic nanoporous surface modification technology. The acquisition will provide the Company with exclusive rights to use and develop Setagon's Controllable Elution Systems (CES) technology in the treatment of cardiovascular disease. Total consideration for Setagon was approximately \$20 in cash, subject to purchase price increases, which would be triggered by the achievement of certain milestones.

On June 25, 2007, the Company exercised a purchase option and acquired substantially all of the O-arm Imaging System (O-arm) assets of Breakaway Imaging, LLC (Breakaway), a privately held company based in Littleton, Massachusetts. Prior to the acquisition, the Company had the exclusive rights to distribute and market the O-arm. The O-arm provides multi-dimensional surgical imaging for use in spinal and orthopedic surgical procedures. The acquisition is expected to bring the O-arm into a broad portfolio of image guided surgical solutions. Total consideration for Breakaway was approximately \$26 in cash, subject to purchase price increases, which would be triggered by the achievement of certain milestones. In connection with the acquisition of Breakaway, the Company acquired \$22 of technology-based intangible assets that had an estimated useful life of 15 years at the time of acquisition, \$1 of tangible assets, and \$3 of goodwill. The goodwill was deductible for tax purposes. The pro forma impact of the acquisition of Breakaway was not significant to the results of the Company for the three and nine months ended January 25, 2008.

Additionally, during the first quarter of fiscal year 2008, the Company recorded IPR&D charges of \$25 related to a milestone payment under the existing terms of a royalty bearing, non-exclusive patent cross-licensing agreement with NeuroPace, Inc. and \$8 for unrelated purchases of certain intellectual property. These payments were expensed as IPR&D since technological feasibility of the underlying projects had not yet been reached and such technology has no future alternative use.

In addition to the acquisitions disclosed above, Medtronic periodically acquires certain tangible or intangible assets in transactions that do not otherwise warrant separate disclosure. These transactions are largely reflected in the condensed consolidated statements of cash flows as a component of investing activities under *purchase of intellectual property*.

Contingent Consideration

Certain of the Company's business combinations or purchases of intellectual property involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. While it is not certain if and/or when these payments will be made, the Company has developed an estimate of the potential contingent consideration for each of its acquisitions with an outstanding potential obligation. At January 23, 2009, the estimated potential amount of future contingent consideration that the Company is expected to make associated with all business combinations or purchases of intellectual property is approximately \$115. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2009 to 2016 in order for the consideration to be paid.

Note 4 Special and Certain Litigation Charges

Special Charges

During the three and nine months ended January 23, 2009, there were no special charges.

During the three and nine months ended January 25, 2008, the Company recorded a special charge of \$78 related to the impairment of intangible assets associated with its benign prostatic hyperplasia, or enlarged prostate, product line purchased in fiscal year 2002. The development of the market, relative to the Company's original assumptions, has changed as a result of the broad acceptance of a new line of drugs to treat the symptoms of an enlarged prostate. After analyzing the estimated future cash flows utilizing this technology, based on the market development, the Company determined that the carrying value of these intangible assets was impaired and a write-down was necessary.

Certain Litigation Charges

The Company classifies material litigation reserves recognized as certain litigation charges.

During the three months ended January 23, 2009, there were no certain litigation charges.

During the nine months ended January 23, 2009, the Company incurred certain litigation charges of \$266. Of the amount recorded, \$229 relates to litigation with Cordis Corporation (Cordis), a subsidiary of Johnson & Johnson (J&J). The Cordis litigation originated in October 1997 and pertains to patent infringement claims on previous generations of bare metal stents that are no longer on the market. On September 30, 2008, the U.S. District Court entered final judgment including accrued interest, totaling approximately \$521, to Cordis. The Company had previously recorded a charge of \$243 related to this litigation in the third quarter of fiscal year 2008. At the time the \$243 charge was recorded, the range of potential loss related to this matter was subject to a high degree of estimation. The amount recorded represented an estimate of the low end of the range of probable outcomes related to the matter. Given that the Company and J&J are involved in a number of litigation matters which span across businesses, the Company entered into negotiations with J&J in an attempt to settle some of the additional litigation simultaneous with the payment of this judgment. Ultimately, the agreement reached with Cordis required a total cash payment of \$472, which included the settlement of several outstanding legal matters between the parties. The charge of \$229 in the nine months ended January 23, 2009 is the net result of \$472 in cash payments, offset by the existing reserves on the balance sheet including interest accrued on the \$243 since the date established.

The remainder of the certain litigation charge of \$37 relates to costs for the settlement of litigation that originated in May 2006 with Fastenetix LLC (Fastenetix), a patent holding company. The litigation related to an alleged breach of a royalty agreement in the Company's Spinal business. The agreement reached with Fastenetix required a total cash payment of \$125 for the settlement of ongoing litigation and the purchase of patents. Of the \$125, \$37 was assigned to past damages in the case and the remaining \$88 was recorded as purchased intellectual property that has an estimated useful life of 7 years. As of October 24, 2008, all of these amounts had been paid.

During the three and nine months ended January 25, 2008, the Company incurred certain litigation charges of \$366. Of the amount recorded, \$123 relates to the settlement of certain lawsuits relating to the Marquis line of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) that were subject to a field action announced on February 10, 2005. The remainder of the charge, \$243, relates to an estimated reserve established for litigation with Cordis.

Note 5 Restructuring Charges

Global Realignment Initiative

In fiscal year 2008, as part of a global realignment initiative, the Company recorded a \$31 restructuring charge, which consisted of employee termination costs of \$27 and asset write-downs of \$4. This initiative began in the fourth quarter of fiscal year 2008 and focuses on shifting resources to those areas where the Company has the greatest opportunities for growth and streamlining operations to drive operating leverage. The global realignment initiative impacts most businesses and certain corporate functions. Within the Company's Cardiac Rhythm Disease Management (CRDM) business, the Company is reducing research and development infrastructure by closing a facility outside the U.S., reprioritizing research and development projects to focus on the core business and consolidating manufacturing operations to drive operating leverage. Within Spinal, the Company is reorganizing and consolidating certain activities where Medtronic's existing infrastructure, resources, and systems can be leveraged to obtain greater operational synergies. The global realignment initiative is also designed to further consolidate manufacturing of CardioVascular products, streamline distribution of products in select businesses and to reduce general and administrative costs in the Company's corporate functions. The asset write-downs were recorded within *cost of products sold* in the condensed consolidated statement of earnings. The employee termination costs of \$27 consist of severance and the associated costs of continued medical benefits and outplacement services.

Edgar Filing: MEDTRONIC INC - Form 10-Q

As a continuation of the global realignment initiative that began in fiscal year 2008, in the first quarter of fiscal year 2009 the Company incurred \$96 of incremental restructuring charges, which consists of employee termination costs of \$91 and asset write-downs of \$5. The majority of the expense recognized in the first quarter of fiscal year 2009 is related to the execution of the Company's global realignment initiative outside the U.S. This includes the realignment and elimination of personnel throughout Europe and the Emerging Markets and the closure of an existing facility in the Netherlands that will be integrated into the U.S. operations. The remainder of the expense is associated with enhanced severance benefits provided to employees identified in the fourth quarter of fiscal year 2008. These incremental costs were not accrued in fiscal year 2008 because the enhanced benefits had not yet been communicated to the impacted employees.

There were no restructuring charges in the second and third quarters of fiscal year 2009.

As of the end of the first quarter of fiscal year 2009, the Company had identified approximately 900 positions for elimination which will be achieved through both voluntary and involuntary separation. Of the 900 positions identified, approximately 570 have been eliminated as of January 23, 2009. The restructuring initiatives are scheduled to be substantially complete by the end of fiscal year 2009.

A summary of the activity related to the global realignment initiative is presented below:

	Global Realignment Initiative		
	Employee Termination Costs	Asset Write-downs	Total
Balance at April 27, 2007	\$	\$	\$
Restructuring charges	27	4	31
Payments/write-downs	(2)	(4)	(6)
Balance at April 25, 2008	\$ 25	\$	\$ 25
Restructuring charges	91	5	96
Payments/write-downs	(18)	(5)	(23)
Balance at July 25, 2008	\$ 98	\$	\$ 98
Payments	(19)		(19)
Currency adjustment, net	(9)		(9)
Balance at October 24, 2008	\$ 70	\$	\$ 70
Payments	(30)		(30)
Currency adjustment, net	4		4
Balance at January 23, 2009	\$ 44	\$	\$ 44

Fiscal Year 2007 Initiative

In fiscal year 2007, the Company recorded a \$36 restructuring charge, which consisted of employee termination costs of \$28 and asset write-downs of \$8. These initiatives were designed to drive manufacturing efficiencies in the Company's CardioVascular business, downsize the Physio-Control business due to the Company's voluntary suspension of U.S. shipments, and rebalance resources within the CRDM business in response to market dynamics. The employee termination costs consist of severance and the associated costs of continued medical benefits, and outplacement services. The asset write-downs consist of a \$5 charge for inventory write-downs and a \$3 charge for non-inventory asset write-downs. The inventory and non-inventory asset write-downs were recorded within *cost of products sold* in the condensed consolidated statement of earnings.

As a continuation of the fiscal year 2007 initiatives, in the first quarter of fiscal year 2008 the Company incurred \$14 of incremental restructuring charges associated with compensation provided to employees whose employment terminated with the Company in the first quarter of fiscal year 2008. These incremental costs were not accrued in fiscal year 2007 because these benefits had not yet been communicated to the impacted employees. Included in the total \$14 restructuring charge is \$4 of incremental defined benefit pension and post-retirement related expense for those employees who accepted early retirement packages. These costs are not included in the table summarizing restructuring costs below because they are associated with costs that are accounted for under the pension and postretirement rules. For further discussion on the incremental defined benefit pension and post-retirement related expense, see Note 17.

Edgar Filing: MEDTRONIC INC - Form 10-Q

When the restructuring initiative began in fiscal year 2007, the Company identified approximately 900 positions for elimination which were achieved through early retirement packages offered to employees, voluntary separation, and involuntary separation, as necessary. As of April 25, 2008, the initiatives begun in the fourth quarter of fiscal year 2007 were substantially complete.

A summary of the activity related to the fiscal year 2007 initiative is presented below:

	Fiscal Year 2007 Initiative		
	Employee Termination Costs	Asset Write-downs	Total
Balance at April 28, 2006	\$	\$	\$
Restructuring charges	28	8	36
Payments/write-downs	(5)	(8)	(13)
Balance at April 27, 2007	23		23
Restructuring charges	10		10
Payments	(33)		(33)
Balance at April 25, 2008	\$	\$	\$

Note 6 Investments

The carrying amounts of cash and cash equivalents approximate fair value due to their short maturities.

Information regarding the Company's *short-term* and *long-term investments* at January 23, 2009 is as follows:

	Cost	Unrealized Gains	Unrealized Losses	Fair Value
Corporate debt securities	\$ 880	\$ 6	\$ (22)	\$ 864
Auction rate securities	202		(71)	131
Mortgage backed securities	829	8	(54)	783
Government and agency securities	492	11		503
Certificates of deposit	2			2
Other asset backed securities	337		(25)	312
Marketable equity securities	12		(4)	8
Cost method, equity method and other investments (1)	498			498
Total short-term and long-term investments	\$ 3,252	\$ 25	\$ (176)	\$ 3,101

(1) Includes \$221 for the 15 percent equity interest in Shandong Weigao Group Medical Polymer Company Limited (Weigao), which was acquired on December 18, 2008. The cash paid for the investment was included in *other investing activities, net* on the condensed consolidated statement of cash flows.

Information regarding the Company's *short-term* and *long-term investments* at April 25, 2008 is as follows:

	Cost	Unrealized Gains	Unrealized Losses	Fair Value
Corporate debt securities	\$ 942	\$ 2	\$ (15)	\$ 929
Auction rate securities	198		(22)	176
Mortgage backed securities	693	3	(17)	679
Government and agency securities	478	1	(3)	476
Other asset backed securities	382	1	(12)	371
Marketable equity securities	14		(1)	13
Cost method, equity method and other investments	231			231
Total short-term and long-term investments	\$ 2,938	\$ 7	\$ (70)	\$ 2,875

Edgar Filing: MEDTRONIC INC - Form 10-Q

Activity related to the Company's short-term and long-term investment portfolio is as follows:

	Three months ended			
	January 23, 2009		January 25, 2008	
	Debt (1)	Equity (2)	Debt (1)	Equity (2)
Proceeds from sales	\$ 861	\$	\$ 1,031	\$ 1
Gross realized gains	\$ 19	\$	\$ 12	\$
Gross realized losses	\$ (2)	\$	\$	\$
Impairment losses recognized	\$ (12)	\$	\$	\$

	Nine months ended			
	January 23, 2009		January 25, 2008	
	Debt (1)	Equity (2)	Debt (1)	Equity (2)
Proceeds from sales	\$ 2,182	\$	\$ 7,966	\$ 25
Gross realized gains	\$ 25	\$	\$ 26	\$ 16
Gross realized losses	\$ (7)	\$	\$ (4)	\$
Impairment losses recognized	\$ (33)	\$ (2)	\$	\$ (1)

(1) Includes available-for-sale (AFS) debt securities.

(2) Includes marketable equity securities, cost method, equity method, and other investments.

The January 23, 2009 balance of AFS debt securities by contractual maturity is shown in the following table at fair value. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows, assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

	January 23, 2009
Due in one year or less	\$ 781
Due after one year through five years	1,599
Due after five years through ten years	58
Due after ten years	157
Total debt securities	\$ 2,595

As of January 23, 2009, the Company has \$273 in debt securities that have been in an unrealized loss position for more than twelve months. The aggregate amount of unrealized losses for these investments is \$63. As of January 23, 2009, the Company has \$884 in debt securities that have been in an unrealized loss position for less than twelve months. The aggregate amount of unrealized losses for these investments is \$109. The majority of these investments are in high quality, investment grade securities. The Company does not consider these unrealized losses to be other-than-temporary as it has the intent and ability to hold these investments long enough to avoid realizing any significant losses.

The Company has investments in marketable debt securities that are classified and accounted for as available-for-sale. The Company's debt securities include government securities, commercial paper, corporate debt securities, bank certificates of deposit, and mortgage backed and other asset backed securities including auction rate securities. Market conditions during the first three quarters of fiscal year 2009 and subsequent to the Company's January 23, 2009 quarter-end continue to indicate significant uncertainty on the part of investors on the economic outlook for the U.S. and for financial institutions. This uncertainty has created reduced liquidity across the fixed income investment market, including certain securities in which the Company has invested. As a result, some of the Company's investments have experienced reduced liquidity including unsuccessful monthly auctions for auction rate security holdings.

For the three and nine months ended January 23, 2009, the Company recognized an other-than-temporary impairment loss on AFS debt securities of \$12 and \$33, respectively. Based on the Company's assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which invested, the Company believes it has recorded all necessary other-than-temporary impairments as the Company has the ability and the intent to hold these investments long enough to avoid realizing further losses. For additional discussion, see the Liquidity and Capital Resources section of management's discussion and analysis.

Edgar Filing: MEDTRONIC INC - Form 10-Q

As of January 23, 2009 and April 25, 2008, the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was \$498 and \$231, respectively. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company's investment may not be recoverable. The fair value of cost or equity method investments is not estimated if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.

Gains and losses recognized on debt instruments are recorded in *interest (income)/expense, net* in the condensed consolidated statements of earnings. Gains and losses recognized on equity instruments are recorded in *other expense, net* in the condensed consolidated statements of earnings. Gains and losses from the sale of investments are calculated based on the specific identification method.

The Company historically lent certain fixed income securities to enhance its investment income. Those lending activities were indemnified against counterparty risk and collateralized at an average rate of 102 percent, with the collateral determined based on the underlying securities and creditworthiness of the borrowers. The value of the securities on loan at April 25, 2008 was \$610. Due to the Company's concerns about the liquidity condition in the fixed income markets, the Company suspended its lending program in the second quarter of fiscal year 2009 and had no lending activity during the third quarter of fiscal year 2009.

Note 7 Fair Value Measurements

As discussed in Note 2, the Company adopted SFAS No. 157 effective April 26, 2008, with respect to fair value measurements of (a) nonfinancial assets and liabilities that are recognized or disclosed at fair value in the Company's financial statements on a recurring basis (at least annually) and (b) all financial assets and liabilities. SFAS No. 157 clarifies the definition of fair value, establishes a framework for measuring fair value, and expands the disclosures on fair value measurements.

Under SFAS No. 157, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. SFAS No. 157 also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows:

Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities. The Company's Level 1 assets include money market funds, treasury bonds, marketable equity securities, and foreign currency hedges that are valued using quoted market prices.

Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. The Company's Level 2 assets and liabilities primarily include agency bonds, corporate debt securities, asset backed securities, and certain mortgage backed securities whose value is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data.

Level 3 - Inputs are unobservable inputs for the asset or liability. The Company's Level 3 assets include certain corporate debt securities, auction rate securities, certain mortgage backed securities, and certain asset backed securities. See the section below titled *Level 3 Valuation Techniques* for further discussion of how the Company determines fair value for investments classified as Level 3.

Assets and Liabilities that are Measured at Fair Value on a Recurring Basis

For the Company, effective April 26, 2008, fair value under SFAS No. 157 is principally applied to financial assets and liabilities such as marketable equity securities and debt securities that are classified and accounted for as available-for-sale, investments in equity and other securities, and certain derivative instruments. Derivatives include cash flow hedges, freestanding derivative forward contracts, and net investment hedges. These items were previously and will continue to be marked-to-market at each reporting period; however, the definition of fair value is now applied using SFAS No. 157. The information in the following paragraphs and tables primarily addresses matters relative to these financial assets and liabilities. Separately, there were no material fair value measurements with respect to nonfinancial assets or liabilities that are recognized or disclosed at fair value in the Company's financial statements on a recurring basis subsequent to the effective date of SFAS No. 157.

Edgar Filing: MEDTRONIC INC - Form 10-Q

The following table provides information by level for assets and liabilities that are measured at fair value, as defined by SFAS No. 157, on a recurring basis.

	Fair Value at January 23, 2009	Fair Value Measurements Using Inputs Considered as		
		Level 1	Level 2	Level 3
Assets:				
Corporate debt securities	\$ 864	\$ 18	\$ 820	\$ 26
Auction rate securities	131			131
Mortgage backed securities	783		744	39
Government and agency securities	503	88	415	
Certificates of deposit	2		2	
Other asset backed securities	312		296	16
Marketable equity securities	8	8		
Derivative assets	496	496		
Total assets	\$ 3,099	\$ 610	\$ 2,277	\$ 212
Liabilities:				
Derivative liabilities	\$ 196	\$ 196		\$
Total liabilities	\$ 196	\$ 196		\$

Level 3 Valuation Techniques

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation. Level 3 investment securities primarily include certain corporate debt securities, auction rate securities, certain mortgage backed securities, and certain asset backed securities for which there was a decrease in the observability of market pricing for these investments. At January 23, 2009, these securities were valued primarily using broker quotes or pricing models that incorporate transaction details such as contractual terms, maturity, timing and amount of future cash flows, as well as assumptions about liquidity and credit valuation adjustments of marketplace participants at January 23, 2009.

The following table provides a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 3).

Balance at April 26, 2008	\$ 448
Total realized losses and other-than-temporary impairment losses included in earnings	(33)
Total unrealized losses included in other comprehensive income	(80)
Purchases, issuances, and settlements	(198)
Net transfers in (out) of Level 3	75
Balance at January 23, 2009	\$ 212

Realized gains or losses included in earnings are included in *interest (income)/expense, net* in the consolidated statement of earnings.

Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis

During the three and nine months ended January 23, 2009, the Company had no significant measurements of financial assets or liabilities at fair value on a nonrecurring basis subsequent to their initial recognition.

The aspects of SFAS No. 157 for which the effective date was deferred under FSP FAS No. 157-2 until fiscal year 2010 relate to nonfinancial assets and liabilities that are measured at fair value, but are recognized or disclosed at fair value on a nonrecurring basis. This deferral applies to such items as nonfinancial assets and liabilities initially measured at fair value in a business combination (but not measured at fair value in subsequent periods) or nonfinancial long-lived asset groups measured at fair value for an impairment assessment.

Note 8 Financing Arrangements**Senior Convertible Notes**

In April 2006, the Company issued \$2,200 of 1.500 percent Senior Convertible Notes due 2011 and \$2,200 of 1.625 percent Senior Convertible Notes due 2013 (collectively, the Senior Convertible Notes). The Senior Convertible Notes were issued at par and pay interest in cash semi-annually in arrears on April 15 and October 15 of each year. The Senior Convertible Notes are unsecured unsubordinated obligations and rank equally with all other unsecured and unsubordinated indebtedness. The Senior Convertible Notes had an initial conversion price of \$56.14 per share. The Senior Convertible Notes may only be converted: (i) during any calendar quarter if the closing price of the Company's common stock reaches 140 percent of the conversion price for 20 trading days during a specified period, or (ii) if specified distributions to holders of the Company's common stock are made or specified corporate transactions occur, or (iii) during the last month prior to maturity of the applicable notes. Upon conversion, a holder would receive: (i) cash equal to the lesser of the principal amount of the note or the conversion value and (ii) to the extent the conversion value exceeds the principal amount of the note, shares of the Company's common stock, cash, or a combination of common stock and cash, at the Company's option. In addition, upon a change in control, as defined in the applicable indentures, the holders may require the Company to purchase for cash all or a portion of their notes for 100 percent of the principal amount of the notes plus accrued and unpaid interest, if any, plus a number of additional make-whole shares of the Company's common stock, as set forth in the applicable indenture. The indentures under which the Senior Convertible Notes were issued contain customary covenants. A total of \$2,500 of the net proceeds from these note issuances were used to repurchase common stock. As of April 2008, pursuant to provisions in the indentures relating to the Company's increase of its quarterly dividend to shareholders, the conversion rates for each of the Senior Convertible Notes is now 17.8715, which correspondingly changed the conversion price per share for each of the Senior Convertible Notes to \$55.96.

Under EITF Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock (EITF No. 00-19), the notes are accounted for similar to traditional convertible debt (that is, as a combined instrument) because the conversion spread meets the requirements of EITF No. 00-19, including the provisions contained in paragraphs 12-32 of EITF No. 00-19. Accordingly, the conversion spread is not separated as a derivative.

Concurrent with the issuance of the Senior Convertible Notes, the Company purchased call options on its common stock in private transactions. The call options allow the Company to receive shares of the Company's common stock and/or cash from counterparties equal to the amounts of common stock and/or cash related to the excess conversion value that it would pay to the holders of the Senior Convertible Notes upon conversion. These call options will terminate upon the earlier of the maturity dates of the related Senior Convertible Notes or the first day all of the related Senior Convertible Notes are no longer outstanding due to conversion or otherwise. The call options, which cost an aggregate \$1,075 (\$699 net of tax benefit), were recorded as a reduction of shareholders' equity.

In separate transactions, the Company sold warrants to issue shares of the Company's common stock at an exercise price of \$76.56 per share in private transactions. Pursuant to these transactions, warrants for 41 million shares of the Company's common stock may be settled over a specified period beginning in July 2011 and warrants for 41 million shares of the Company's common stock may be settled over a specified period beginning in July 2013 (the settlement dates). If the average price of the Company's common stock during a defined period ending on or about the respective settlement dates exceeds the exercise price of the warrants, the warrants will be settled in shares of the Company's common stock. Proceeds received from the issuance of the warrants totaled approximately \$517 and were recorded as an addition to shareholders' equity. In April 2008, certain of the holders requested adjustment to the exercise price of the warrants from \$76.47 to \$76.30 pursuant to the anti-dilution provisions of the warrants relating to the Company's payment of dividends to common shareholders.

EITF No. 00-19 provides that contracts are initially classified as equity if (1) the contract requires physical settlement or net-share settlement, or (2) the contract gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The settlement terms of the Company's purchased call options and sold warrant contracts provide for net cash settlement for the particular contract or net share settlement, depending on the method of settlement, as discussed above, which is at the option of the Company. Based on the guidance from EITF No. 00-19 and SFAS No. 133, the purchased call option contracts were recorded as a reduction of equity and the warrants were recorded as an addition to equity as of the trade date. SFAS No. 133 states that a reporting entity shall not consider contracts to be derivative instruments if the contract issued or held by the reporting entity is both indexed to its own stock and classified in shareholders' equity in its statement of financial position. The Company concluded the purchased call option contracts and the warrant contracts should be accounted for in shareholders' equity.

Senior Notes

In September 2005, the Company issued two tranches of Senior Notes with the aggregate face value of \$1,000. The first tranche consisted of \$400 of 4.375 percent Senior Notes due 2010 and the second tranche consisted of \$600 of 4.750 percent Senior Notes due 2015. Each tranche was issued at a discount which resulted in an effective interest rate of 4.433 percent and 4.760 percent for the five and ten year Senior Notes, respectively. Interest on each series of Senior Notes is payable semi-annually, on March 15 and September 15 of each year. The Senior Notes are unsecured unsubordinated obligations of the Company and rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which Senior Notes were issued contain customary covenants. The Company used the net proceeds from the sale of the Senior Notes for repayment of a portion of its commercial paper.

In November 2005 and June 2007, the Company entered into a five year interest rate swap agreement with a notional amount of \$200, and an eight year interest rate swap agreement with a notional amount of \$300, respectively. These interest rate swap agreements were designated as fair value hedges of the changes in fair value of a portion of the Company's fixed-rate \$400 Senior Notes due 2010 and fixed-rate \$600 Senior Notes due 2015, respectively. The outstanding market values of these swap agreements were \$8 and \$27 unrealized gain, respectively, at April 25, 2008. The unrealized gains of \$8 and \$27 at April 25, 2008 were recorded in *long-term debt* with the offset recorded in *other assets* on the condensed consolidated balance sheets.

In December 2008, the Company terminated the interest rate swap agreements. At that time, the contracts were in an asset position, resulting in cash receipts of \$62, which included \$3 of accrued interest. The gain from terminating the interest rate swap agreements will increase the outstanding balance of the Senior Notes and will be amortized as a reduction of interest expense over the remaining life of the Senior Notes. The cash flows from the termination of these interest rate swap agreements are reported as operating activities in the condensed consolidated statement of cash flows.

Contingent Convertible Debentures

As of January 23, 2009, the Company has \$15 remaining in aggregate principle amount of 1.250 percent Contingent Convertible Debentures, Series B due 2021 (the Debentures) outstanding. Interest is payable semi-annually. Each Debenture is convertible into shares of common stock at an initial conversion price of \$61.81 per share; however, the Debentures are not convertible before their final maturity unless the closing price of the Company's common stock reaches 110 percent of the conversion price for 20 trading days during a consecutive 30 trading day period. Upon conversion of the Debentures, the Company will pay holders cash equal to the lesser of the principal amount of the Debentures or their conversion value, and shares of the Company's common stock to the extent the conversion value exceeds the principal amount of the Debentures. The Company may be required to repurchase the remaining debentures at the option of the holders in September 2011 or 2016. For put options exercised by the holders of the Debentures, the purchase price is equal to the principal amount of the applicable debenture plus any accrued and unpaid interest thereon to the repurchase date. If the put option is exercised, the Company will pay holders the repurchase price solely in cash. In September 2008, as a result of certain holders of the Debentures exercising their put options, the Company repurchased \$79 of the Debentures for cash. The Company can redeem the remaining debentures for cash at any time.

Commercial Paper

The Company maintains a commercial paper program that allows the Company to have a maximum of \$2,250 in commercial paper outstanding, with maturities up to 364 days from the date of issuance. As of January 23, 2009 and April 25, 2008, outstanding commercial paper totaled \$1,011 and \$874, respectively. During the three and nine months ended January 23, 2009, the weighted average original maturity of the commercial paper outstanding was approximately 65 days and 48 days, respectively, and the weighted average interest rate was 1.49 percent and 1.93 percent, respectively. The issuance of commercial paper reduces the amount of credit available under the Company's existing lines of credit.

Lines of Credit

The Company has existing unsecured lines of credit of approximately \$2,850 with various banks at January 23, 2009. The existing lines of credit include a five-year \$1,750 syndicated credit facility dated December 20, 2006 that will expire on December 20, 2011 (Credit Facility). The Credit Facility provides backup funding for the commercial paper program and may also be used for general corporate purposes.

The Credit Facility provides the Company with the ability to increase its capacity by an additional \$500 at any time during the life of the five-year term of the agreement.

Interest rates on these borrowings are determined by a pricing matrix, based on the Company's long-term debt ratings, assigned by Standard and Poor's Ratings Group and Moody's Investors Service. Facility fees are payable on the credit facilities and are determined in the same manner as the interest rates.

Edgar Filing: MEDTRONIC INC - Form 10-Q

On November 2, 2007, the Company entered into a new Credit Agreement (New Credit Agreement) with the Bank of Tokyo-Mitsubishi UFJ, Ltd. (New Lender). The New Credit Agreement provides for a \$300 unsecured revolving credit facility (New Facility) maturing November 2, 2010. In addition to certain initial fees, the Company is obligated to pay a commitment fee based on the total revolving commitment. Interest rates on these borrowings are determined by a pricing matrix, based on the Company's long-term debt ratings, assigned by Standard and Poor's Ratings Group and Moody's Investors Service. The New Credit Agreement contains customary representations and warranties of the Company as well as affirmative covenants regarding the Company. Upon the occurrence of an event of default as defined under the New Credit Agreement, the New Lender could elect to declare all amounts outstanding under the New Facility to be immediately due and payable. As of January 23, 2009 and April 25, 2008, \$0 and \$300, respectively, were outstanding on the New Facility.

Note 9 Inventories

Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:

	January 23, 2009	April 25, 2008
Finished goods	\$ 853	\$ 784
Work in process	249	250
Raw materials	327	246
Total	\$ 1,429	\$ 1,280

Note 10 Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill for the nine months ended January 23, 2009 are as follows:

	January 23, 2009
Balance at April 25, 2008	\$ 7,519
Goodwill as a result of acquisitions	239
Currency adjustment, net	(14)
Balance at January 23, 2009	\$ 7,744

Intangible assets, excluding goodwill, as of January 23, 2009 and April 25, 2008 are as follows:

	Purchased Technology and Patents	Trademarks and Tradenames	Other	Total
As of January 23, 2009:				
Amortizable intangible assets				
Original cost	\$ 2,701	\$ 373	\$ 245	\$ 3,319
Accumulated amortization	(751)	(208)	(174)	(1,133)
Carrying value	\$ 1,950	\$ 165	\$ 71	\$ 2,186

As of April 25, 2008:

Amortizable intangible assets				
Original cost	\$ 2,538	\$ 373	\$ 244	\$ 3,155
Accumulated amortization	(616)	(181)	(165)	(962)
Carrying value	\$ 1,922	\$ 192	\$ 79	\$ 2,193

Amortization expense for the three and nine months ended January 23, 2009 was \$74 and \$209, respectively, and for the three and nine months ended January 25, 2008 was \$64 and \$151, respectively.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows:

Fiscal Year	Amortization Expense
Remaining 2009	\$ 63
2010	271
2011	265
2012	235
2013	220
Thereafter	1,132
	\$ 2,186

Note 11 Warranty Obligation

The Company offers a warranty on various products. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Factors that affect the Company's warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. The amount of the reserve recorded is equal to the costs to repair or otherwise satisfy the claim.

Changes in the Company's product warranties during the nine months ended January 23, 2009 and January 25, 2008 consist of the following:

	Nine months ended	
	January 23, 2009	January 25, 2008
Balance at the beginning of the period	\$ 43	\$ 34
Warranty claims provision	17	20
Settlements made	(23)	(16)
Balance at the end of the period	\$ 37	\$ 38

Note 12 Interest (Income)/Expense, net

Interest income and interest expense for the three and nine months ended January 23, 2009 and January 25, 2008 are as follows:

	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Interest income	\$ (54)	\$ (84)	\$ (148)	\$ (307)
Interest expense	52	75	165	193
Interest (income)/expense, net	\$ (2)	\$ (9)	\$ 17	\$ (114)

Interest income includes interest earned on the Company's cash and cash equivalents, short- and long-term investments and the net realized gain or loss on the sale or impairment of AFS debt securities.

Interest expense includes the expense associated with the interest that the Company pays on its outstanding borrowings, including short- and long-term instruments, and the amortization of debt issuance costs.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Note 13 Income Taxes

During the three months ended January 23, 2009, the Company recorded \$12 in operational tax benefits for the finalization of certain tax returns and changes to uncertain tax position reserves. During the comparative three months ended January 25, 2008, the Company recorded \$30 in operational tax benefits for the finalization of certain tax returns and changes to uncertain tax position reserves. Lastly, during the nine months ended January 23, 2009, the Company also recorded a \$16 operational tax benefit associated with the retroactive renewal and extension of the research and development credit enacted by the Tax Extenders and Alternative Minimum Tax Relief Act of 2008. The \$16 tax benefit related to a retroactive adjustment for the first seven months of calendar year 2008. The research and development credit related to subsequent months is included in the rate from the second quarter of fiscal year 2009 and forward. These tax adjustments are operational in nature and are recorded in *provision for income taxes* on the condensed consolidated statements of earnings.

As of January 23, 2009, the Company had \$480 of gross unrecognized tax benefits and accrued interest and penalties of \$153. If all of the Company's unrecognized tax benefits were recognized, approximately \$398 would impact the Company's effective tax rate. The Company expects to receive the U.S. Internal Revenue Service (IRS) field audit report for fiscal years 2005 and 2006 within the next twelve months. However, based on the status of the IRS field audit, the Company cannot reasonably estimate the potential changes to its unrecognized tax benefits. The Company continues to record the liability for unrecognized tax benefits as a long-term liability as it does not expect significant payments to occur or the total amount of unrecognized tax benefits to change significantly over the next twelve months. The Company will continue to recognize interest and penalties related to income tax matters in the *provision for income taxes* in the condensed consolidated statement of earnings and record the liability in the current or long-term *accrued income taxes* in the condensed consolidated balance sheet, as appropriate.

Tax audits associated with the allocation of income, and other complex issues, may require an extended period of time to resolve and may result in income tax adjustments if changes to the Company's allocation are required between jurisdictions with different tax rates. Tax authorities periodically review the Company's tax returns and propose adjustments to the Company's tax filings. The IRS has settled its audits with the Company for all years through fiscal year 1996. Tax years settled with the IRS may remain open for foreign tax audits and competent authority proceedings. Competent authority proceedings are a means to resolve intercompany pricing disagreements between countries.

In August 2003, the IRS proposed adjustments arising out of its audit of the fiscal years 1997, 1998 and 1999 tax returns. The Company initiated a defense of these adjustments at the IRS appellate level, and in the second quarter of fiscal year 2006 the Company reached settlement on most, but not all matters. The remaining issue relates to the allocation of income between Medtronic, Inc., and its wholly owned subsidiary in Switzerland. On April 16, 2008, the IRS issued a statutory notice of deficiency with respect to this remaining issue. The Company filed a Petition with the U.S. Tax Court on July 14, 2008 objecting to the deficiency and intends to defend its position vigorously.

In September 2005, the IRS issued its audit report for fiscal years 2000, 2001 and 2002. In addition, the IRS issued its audit report for fiscal years 2003 and 2004 in March 2007. The Company has reached agreement with the IRS on substantially all of the proposed adjustments for fiscal years 2000 through 2004. The only item of significance that remains open for these years relates to the carryover impact of the allocation of income issue proposed for fiscal years 1997 through 1999, as described in the preceding paragraph.

The unresolved issue from the 1997 through 2004 tax audits, as well as tax positions taken by the IRS or foreign tax authorities during future tax audits, could have a material unfavorable impact on the Company's effective tax rate in future periods. The Company continues to believe that it has meritorious defenses for its tax filings and will vigorously defend them through litigation in the courts, as necessary.

Note 14 Earnings Per Share

Basic earnings per share is computed based on the weighted average number of common shares outstanding. Diluted earnings per share is computed based on the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

Presented below is a reconciliation between basic and diluted earnings per share:

(shares in millions)	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Numerator:				
Net earnings	\$ 723	\$ 77	\$ 2,041	\$ 1,418
Denominator:				

Edgar Filing: MEDTRONIC INC - Form 10-Q

Basic weighted average shares outstanding	1,115.0	1,126.9	1,118.7	1,132.9
Effect of dilutive securities:				
Employee stock options	0.3	7.3	3.2	10.4
Other	4.2	0.8	3.7	2.0
Diluted weighted average shares outstanding	1,119.5	1,135.0	1,125.6	1,145.3
Basic earnings per share	\$ 0.65	\$ 0.07	\$ 1.82	\$ 1.25
Diluted earnings per share	\$ 0.65	\$ 0.07	\$ 1.81	\$ 1.24

20

Edgar Filing: MEDTRONIC INC - Form 10-Q

The calculation of weighted average diluted shares outstanding excludes options for approximately 91 million and 62 million common shares for the three and nine months ended January 23, 2009, respectively, and approximately 43 million and 21 million for the three and nine months ended January 25, 2008, respectively, as the exercise price of those options was greater than the average market price for the period, resulting in an anti-dilutive effect on diluted earnings per share. For the three and nine months ended January 23, 2009 and January 25, 2008, common share equivalents related to the Company's \$4,400 of Senior Convertible Notes were anti-dilutive as the market price of the Company's stock was below the conversion price of the Senior Convertible Notes and, therefore, were excluded from the calculation of weighted average diluted shares.

Note 15 Comprehensive Income and Accumulated Other Comprehensive Income/(Loss)

In addition to net earnings, comprehensive income includes changes in foreign currency translation adjustments (including the change in current exchange rates, or spot rates, of net investment hedges), unrealized gains and losses on foreign exchange derivative contracts qualifying and designated as cash flow hedges, net changes in retirement obligations, and unrealized gains and losses on AFS marketable securities.

Comprehensive income for the three months ended January 23, 2009 and January 25, 2008 was \$644 and \$88, respectively. Comprehensive income for the nine months ended January 23, 2009 and January 25, 2008 was \$2,292 and \$1,361, respectively.

Presented below is a summary of activity for each component of *accumulated other comprehensive income/(loss)*:

	Unrealized Gain/(Loss) on Investments	Cumulative Translation Adjustments	Net Change in Retirement Obligations	Unrealized Gain/(Loss) on Foreign Exchange Derivatives	Accumulated Other Comprehensive Income/(Loss)
Balance April 25, 2008	\$ (41)	\$ 209	\$ (189)	\$ (266)	\$ (286)
Period Change	(9)	2	1	85	78
Balance July 25, 2008	\$ (50)	\$ 211	\$ (188)	\$ (181)	\$ (208)
Period Change	(51)	(134)	14	423	252
Balance October 24, 2008	\$ (101)	\$ 77	\$ (174)	\$ 242	\$ 44
Period Change	5	(28)	1	(57)	(79)
Balance January 23, 2009	\$ (96)	\$ 49	\$ (173)	\$ 185	\$ (35)

Translation adjustments are not adjusted for income taxes as substantially all translation adjustments relate to permanent investments in non-U.S. subsidiaries. The tax expense/(benefit) on the unrealized gain/(loss) on foreign exchange derivatives for the three and nine months ended January 23, 2009 was \$(36) and \$293, respectively. The tax benefit on the unrealized gain/(loss) on investments for the three and nine months ended January 23, 2009 was \$2 and \$34, respectively. The tax benefit on the net change in retirement obligations was not material for the three and nine months ended January 23, 2009.

Note 16 Stock-Based Compensation

In fiscal year 2007, the Company adopted FASB SFAS No. 123 (revised 2004), *Share-Based Payment* (SFAS No. 123(R)) which replaced SFAS No. 123, *Accounting for Stock-Based Compensation* (SFAS No. 123) and superseded Accounting Principles Board (APB) Opinion No. 25,

Accounting for Stock Issued to Employees. Under the fair value recognition provisions of SFAS No. 123(R), the Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The Company elected the modified-prospective method of adopting SFAS No. 123(R), under which prior periods were not retroactively restated. The provisions of SFAS No. 123(R) apply to awards granted after the April 29, 2006 effective date. Stock-based compensation expense for the non-vested portion of awards granted prior to the effective date is being recognized over the remaining service period using the fair-value based compensation cost estimated for SFAS No. 123 pro forma disclosures.

Edgar Filing: MEDTRONIC INC - Form 10-Q

The following table presents the components and classification of stock-based compensation expense recognized for the three and nine months ended January 23, 2009 and January 25, 2008:

	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Stock options	\$ 41	\$ 46	\$ 107	\$ 104
Restricted stock awards	25	22	59	47
Employee stock purchase plan	4	3	12	12
Total stock-based compensation expense	\$ 70	\$ 71	\$ 178	\$ 163
Cost of products sold	\$ 8	\$ 8	\$ 21	\$ 19
Research and development expense	17	17	43	39
Selling, general and administrative expense	45	46	114	105
Total stock-based compensation expense	\$ 70	\$ 71	\$ 178	\$ 163

In connection with the acquisition of Kyphon on November 2, 2007, the Company assumed Kyphon's unvested stock-based awards. These awards are amortized over 2.5 years, which was their remaining weighted average vesting period at the time of acquisition. For the three and nine months ended January 23, 2009, the Company recognized \$4 and \$17, respectively, of stock-based compensation expense associated with the assumed Kyphon awards. For both the three and nine months ended January 25, 2008, the Company recognized \$13 of stock-based compensation expense associated with the assumed Kyphon awards. See Note 3 for further discussion of the Kyphon acquisition.

Note 17 Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans (post-retirement benefits), defined contribution savings plans and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the pension and post-retirement medical plans include the following components for the three and nine months ended January 23, 2009 and January 25, 2008:

	U.S. Pension Benefits Three months ended		Non-U.S. Pension Benefits Three months ended		Post-Retirement Benefits Three months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Service cost	\$ 18	\$ 18	\$ 8	\$ 8	\$ 4	\$ 4
Interest cost	15	13	6	4	3	3
Expected return on plan assets	(25)	(21)	(6)	(5)	(3)	(3)
Recognized actuarial loss	1	3		1		1
Net periodic benefit cost	9	13	8	8	4	5
Special termination benefits						
Total cost for period	\$ 9	\$ 13	\$ 8	\$ 8	\$ 4	\$ 5

	U.S. Pension Benefits Nine months ended		Non-U.S. Pension Benefits Nine months ended		Post-Retirement Benefits Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Service cost	\$ 54	\$ 54	\$ 24	\$ 23	\$ 12	\$ 12
Interest cost	45	39	18	12	9	9
Expected return on plan assets	(74)	(63)	(18)	(14)	(9)	(9)
Recognized actuarial loss	3	9		2		2
Net periodic benefit cost	28	39	24	23	12	14
Special termination benefits		3				1
Total cost for period	\$ 28	\$ 42	\$ 24	\$ 23	\$ 12	\$ 15

Edgar Filing: MEDTRONIC INC - Form 10-Q

As a result of the fiscal year 2007 restructuring initiative that began in the fourth quarter of fiscal year 2007, the Company has recognized special termination benefits in the nine months ended January 25, 2008 related to employees electing to accept early retirement packages provided under the restructuring initiatives. The incremental expense from these special termination benefits is reflected in the table above.

Note 18 Contingencies

The Company is involved in a number of legal actions. The outcomes of these legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, that could require significant expenditures or result in lost revenues. In accordance with SFAS No. 5, Accounting for Contingencies (SFAS No. 5), the Company records a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the matters discussed, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company's consolidated earnings, financial position or cash flows.

Litigation with Wyeth and Cordis Corporation

On February 22, 2008, Wyeth and Cordis filed a lawsuit against the Company and its subsidiary, Medtronic AVE, Inc., in U.S. District Court for the District of New Jersey, alleging that Medtronic's Endeavor drug eluting stent infringes three U.S. Morris patents alleged to be owned by Wyeth and exclusively licensed to Cordis. The Company believes it is indemnified for the claims made by Wyeth and Cordis. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.

Litigation with Johnson & Johnson and Cordis Corporation

On February 20, 2006, an arbitration panel issued a final, non-appealable award concluding that Medtronic Vascular's S670, S660, S540, S7 and Driver stents, which were formerly the subject of a patent infringement dispute between J&J and Cordis and Medtronic Vascular, are licensed under a 1997 agreement between the two companies and subject to a covenant not to sue contained within a 1998 amendment to the 1997 agreement. Cordis since initiated six arbitration proceedings against Medtronic Vascular alleging that certain of the products infringe certain patents of J&J and Cordis, and is seeking royalties for such infringement, if any. The first arbitration proceeding has been rescheduled to start July 27, 2009, and will determine whether multiple Medtronic stent products are infringing a single Cordis patent. Each of the remaining five arbitrations, however, as required under the 1997 agreement, will only address whether a single Medtronic stent product infringes another group of Cordis patents. The first of the remaining five arbitrations is being scheduled for early fall 2009, but dates have not been set for hearings for the remaining arbitrations. The Company has not recorded an expense related to damages in this matter because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.

Litigation with Abbott Cardiovascular Systems Inc.

On December 24, 1997, Abbott Cardiovascular Systems Inc. (ACS), a subsidiary of Abbott Laboratories (Abbott), sued Medtronic Vascular in U.S. District Court for the Northern District of California alleging that certain models of Medtronic Vascular's bare metal stents infringe the Lau stent patents held by ACS, and seeking injunctive relief and monetary damages. In February 2005, following trial in Delaware federal district court, a jury determined that the ACS Lau stent patents were valid and that Medtronic's Driver, GFX, MicroStent, S540, S660, S670, Bestent2 and S7 stents (the bare metal stents) infringe those patents. Medtronic Vascular made numerous post-trial motions challenging the jury's verdict of infringement and validity. In August 2005, the Court issued an order continuing a stay of any further proceedings on the questions of damages or willful infringement.

Edgar Filing: MEDTRONIC INC - Form 10-Q

On March 30, 2007, the District Court denied Medtronic's post-trial motions, and on April 24, 2007, the District Court ruled that the patents were enforceable. In May 2007, the District Court entered judgment in favor of ACS and against Medtronic Vascular on the issues of validity, infringement and enforceability of the Lau patents. On May 18, 2007, the District Court confirmed that a trial on issues of damages or willful infringement would be deferred pending the U.S. Court of Appeals for the Federal Circuit review of the liability issues concerning alleged infringement, invalidity and inequitable conduct.

ACS filed a motion for injunction in the District Court on June 29, 2007 on both the bare metal stents and the Endeavor drug eluting stent, which had never previously been named as an accused product in the lawsuit. On July 6, 2007, Medtronic filed its motion to stay ACS's June 29, 2007 motion for a permanent injunction pending arbitration under a 2002 agreement with Abbott providing Medtronic with a license that Medtronic asserted precluded the ACS injunction motion.

On August 6, 2007, the Delaware District Court granted Medtronic's July 6, 2007 motion to stay, in part, permitting arbitration to proceed on Medtronic's assertion that it has a license to practice the U.S. Lau patents in its Endeavor stent. On February 26, 2008, an arbitrator concluded that the Company was not licensed to practice the U.S. Lau patents in its Endeavor stent and ACS filed a sealed motion with the District Court seeking to lift the July 6, 2007 stay of proceedings on ACS's motion for an injunction as to Endeavor. On September 29, 2008, the Delaware District Court granted ACS's motion to lift the stay of proceedings with regard to Endeavor and then denied ACS's motion for a permanent injunction with respect to both Driver and Endeavor. On October 2, 2008, Medtronic filed its Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit with respect to the May 2007 judgment in favor of ACS, and all other adverse rulings to Medtronic. On October 15, 2008, ACS appealed from the District Court's September 29, 2008 order denying ACS's request for a permanent injunction. Medtronic filed its principal brief in the appeal on January 26, 2009. Briefing is expected to be completed by early June 2009, after which the U.S. Court of Appeals for the Federal Circuit will set a date for hearing oral argument.

On June 18, 2008, Abbott initiated legal proceedings in the Netherlands against Medtronic BV, Medtronic Trading NL BV and BV Medtronic FSC asserting that certain of Medtronic's Driver, Endeavor and Endeavor Resolute large vessel diameter stents infringe an Abbott European Lau patent issued on June 18, 2008. A hearing took place on August 7, 2008 in the Netherlands district court in The Hague to consider Abbott's request for a preliminary injunction against infringement in the Netherlands. On August 28, 2008, the court granted Abbott a preliminary injunction against Medtronic prohibiting Medtronic from making, selling and distributing certain large vessel diameter Medtronic stents in the Netherlands. The affected stents are Medtronic's large vessel stents, 4.0mm and larger and one stent sized 3.5mm by 9mm. The injunction does not apply outside of the Netherlands, and Medtronic has alternative means in place for distribution of the affected stents outside of the Netherlands while the preliminary injunction remains in effect. Medtronic has appealed the preliminary decision and on February 6, 2009 challenged the preliminary ruling at a full trial on the merits. A trial decision is expected on April 8, 2009. The European Lau patent remains subject to challenges to the patent's validity in opposition proceedings in the European patent office as well as in the proceedings in court in the Netherlands. Abbott has filed similar lawsuits against Medtronic's large vessel bare metal stents in France, Germany and Japan. In the German proceeding, a trial date is set for August 2009. In France, a trial is scheduled for July 2009. In Japan, a series of hearings will be held throughout 2009, beginning on February 2, 2009.

In response to Medtronic's Request for Reexamination for each of the four Lau patents, in December 2006, the USPTO issued an initial office action finding that the claims which Medtronic products were previously found to have infringed were not patentable. The USPTO granted a second petition to reexamine each of the four Lau patents in 2007. On June 30, 2008, the USPTO determined for a second time that all of the claims of the earliest Lau patent (US 5,514,154) that Medtronic was found to infringe were invalid. After granting a third petition to reexamine two of the other four Lau patents (US 6,066,167 and 6,066,168) in 2008, on September 30, 2008, the USPTO again determined that all claims of those two Lau patents that Medtronic was found to have infringed were invalid. Finally, with respect to the fourth and latest issued Lau patent (US 6,432,133), on March 3, 2008, the USPTO again determined that all claims of this Lau patent that Medtronic was found to infringe were invalid with the exception of a single claim. This latest issued Lau patent is involved in a reexamination proceeding, which allows Medtronic to participate in the USPTO proceedings. Responses to the USPTO's rejection of the claims of this patent were filed by both parties in October 2008. The patent holder will have an opportunity to challenge the USPTO's determinations in further proceedings in the reexaminations. Until these reexaminations are concluded, their potential impact upon the claims relating to the Lau patents in the above proceeding remains unknown.

The Company has not recorded an expense related to damages in this matter because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.

Litigation with DePuy Spine

On January 26, 2001, DePuy Spine (formerly DePuy/AcroMed), a subsidiary of J&J, and Biedermann Motech GmbH (collectively, DePuy) filed suit in U.S. District Court for the District of Massachusetts alleging that Medtronic's subsidiary, Medtronic Sofamor Danek USA, Inc. (MSD), was infringing a patent relating to a design for a thoracolumbar multi-axial screw (MAS). DePuy subsequently supplemented its allegations to claim that MSD's M10, M8 and Vertex screws infringe the patent. On April 17, 2003 and February 26, 2004, the District Court ruled on summary judgment that the M10, M8 and Vertex screws do not infringe. On October 1, 2004, a jury found that MAS screws, which MSD no longer sells in the U.S., infringe under the doctrine of equivalents. The jury awarded damages of \$21 and on February 9, 2005, the Court entered judgment against MSD, including prejudgment interest, in the aggregate amount of \$24. In the third quarter of fiscal year 2005, the Company recorded an expense equal to the \$24 judgment in the matter. DePuy appealed the Court's decisions that the M10, M8 and Vertex screws do not infringe, and MSD appealed the jury's verdict that the MAS screws infringe valid claims of the patent. On November 20, 2006, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the District Court that the M10 and M8 screws do not infringe, affirmed the jury's verdict and damage award on the MAS screws, affirmed the decision that the Vertex screws do not literally infringe, but remanded the case, ruling that there is a triable issue of fact as to whether the Vertex screws infringe under the doctrine of equivalents. On remand, DePuy further supplemented its allegations to claim that an additional product, the Vertex Max screws, also infringe. On March 20, 2007, the District Court declined to stay execution of the judgment relating to the MAS product. On March 30, 2007, the judgment plus accrued interest was paid under protest. On September 27, 2007, a jury found that the Vertex and Vertex Max screws infringe under the doctrine of equivalents and awarded \$226 in damages to DePuy, and the District Court entered judgment against Medtronic on December 12, 2007. Thereafter, the District Court ruled on all post-trial motions, increasing the award to DePuy to an estimated amount of \$272. The District Court also granted a permanent injunction against Medtronic that prohibits Medtronic from making, using and selling Vertex and Vertex Max polyaxial screws in the U.S.; however, Medtronic's recently-introduced Vertex Select multi-axial screw is not affected by the injunction. Medtronic has appealed to the U. S. Court of Appeals for the Federal Circuit. DePuy has cross-appealed. Oral arguments occurred on January 5, 2009. The Company believes that an unfavorable outcome in this matter is not probable. Accordingly, the Company has not recorded any additional expense related to damages in this matter because any potential loss is not currently probable under SFAS No. 5.

Litigation with Cross Medical Products, Inc.

On May 2, 2003, Cross Medical Products, Inc. (Cross) sued MSD in the U.S. District Court for the Central District of California. The suit alleged that MSD's CD Horizon, Vertex and Crosslink products infringe certain patents owned by Cross. MSD countered that Cross's cervical plate products infringe certain patents of MSD, and Cross has filed a reply alleging that certain MSD cervical plate products infringe certain patents of Cross. Separately, on February 1, 2006, MSD filed a lawsuit in the U.S. District Court for the District of New Jersey against Biomet Inc., the corporate parent of Cross (Biomet) and its subsidiary EBI Spine, L.P., for patent infringement. On December 12, 2008, Medtronic, through its subsidiaries, settled the above litigation with Cross and Biomet.

Marquis/Maximo/InSync Matters

On February 10, 2005, Medtronic voluntarily began to advise physicians about the possibility that a specific battery shorting mechanism might manifest itself in a subset of ICDs and cardiac resynchronization therapy-defibrillators (CRT-Ds). These included certain Marquis VR/DR and Maximo VR/DR ICDs and certain InSync I/II/III CRT-D devices. Subsequent to this voluntary field action, a number of lawsuits were filed against the Company alleging a variety of claims, including individuals asserting claims of personal injury and third party payors alleging entitlement to reimbursement. Many of these lawsuits were settled, and in the third quarter of fiscal year 2008, the Company recorded an expense of \$123 relating to the settlement in accordance with SFAS No. 5 as the potential loss was both probable and reasonably estimable. The Company paid substantially all of the \$123 in the first quarter of fiscal year 2009. Currently, there remain a limited number of immaterial, individual lawsuits and one third party payor putative class action relating to the same subject matter. In addition, class action product liability suits pending in Canada are consolidated in the Ontario Superior Court of Justice. That court certified a class proceeding on December 6, 2007 and denied Medtronic's leave to appeal certification on May 15, 2008. The class was certified to include individual implant recipients and their family members. In addition, the subrogated claims of the provincial health insurers to recover costs incurred in providing medical services to the implant class are claimed in the class proceeding. The court-ordered procedure for providing notice to potential class members has commenced and document discovery is under way. Discovery is expected to be completed during 2009. The Company has not recorded an expense related to damages for the remaining suits because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.

Sprint Fidelis Product Liability Matters

On October 15, 2007, the Company voluntarily suspended worldwide distribution of its Sprint Fidelis (Fidelis) family of defibrillation leads. The leads are used to deliver therapy in patients with ICDs, but are generally not used in pacemaker patients. The U.S. Food and Drug Administration (FDA) subsequently classified the Company's action as a Class I recall. As of March 2, 2009, approximately 1,060 lawsuits regarding the Fidelis leads have been filed against the Company, including approximately 37 putative class action suits reflecting a total of approximately 2,100 individual personal injury cases. In general, the suits allege claims of product liability, warranty, negligence, unjust enrichment, emotional distress and consumer protection violations. One lawsuit includes a claim by an individual purporting to act as a surrogate for the Center for Medicare and Medicaid Services, and one lawsuit has been brought by a third party payor as a putative class action suit. In addition, one putative class action has been filed in the Ontario Superior Court of Justice in Canada. Approximately 300 of the lawsuits have been filed in state court, generally alleging similar causes of action. Of those state court actions, approximately 280 are consolidated before a single judge in Hennepin County District Court in the state of Minnesota. The federal court cases have been consolidated for pretrial proceedings before a single federal judge in the U.S. District Court for the District of Minnesota pursuant to the Multi-District Litigation (MDL) rules. On January 5, 2009, the MDL court entered an order dismissing with prejudice the master consolidated complaint for individuals and the master consolidated complaint for third party payors on grounds of federal preemption. On February 5, 2009, the court denied plaintiffs' request to file a motion for reconsideration of the dismissals with prejudice and granted plaintiffs' request to file a motion seeking permission to amend the master consolidated complaint for individuals. Plaintiffs filed their motion for leave to amend on February 27, 2009; Medtronic's opposition to the request to amend is due March 20, 2009. Discovery in the MDL and the Minnesota state court continues to be stayed pending further proceedings.

The Company has not recorded an expense related to damages in connection with the matter because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.

Shareholder Related Matters

On November 8, 2007, a putative class action complaint was filed against the Company and certain of its officers in the U.S. District Court for the District of Minnesota, alleging violations of Section 10(b) of the Securities Exchange Act of 1934 (the Exchange Act) and Rule 10b-5 thereunder. The complaint is brought on behalf of persons or entities who purchased securities of Medtronic during the period of June 25, 2007 through October 15, 2007. The complaint alleges that materially false and misleading representations were made as to the market acceptance and use of the Fidelis defibrillator leads to artificially inflate Medtronic's stock price. Pursuant to court order, the caption of the case was changed to Medtronic, Inc., Securities Litigation, and a consolidated putative class action complaint was filed on April 18, 2008. The Company filed a motion to dismiss the consolidated class action complaint with prejudice, and a hearing occurred on January 27, 2009.

On November 29 and December 14, 2007 respectively, Feivel Gottlieb and Alan Weinberg filed shareholder derivative actions in Hennepin County District Court in the state of Minnesota against both the Company and certain of its officers and directors, alleging breach of fiduciary duty, waste of corporate assets and other claims arising from the same subject matter as the consolidated class action complaint. On July 28, 2008, the state court stayed these actions pending final resolution of the related consolidated class action complaint.

Similarly, on January 9, 2008, Iris Markewich filed a shareholder derivative action against both the Company and certain of its officers, directors, and employees (the defendants) in the U.S. District Court for the District of Minnesota, alleging breach of fiduciary duty, waste of corporate assets and other claims arising from the same subject matter as the consolidated class action complaint. After the defendants moved to dismiss the complaint, the plaintiffs amended their complaint to add similar allegations relating to alleged off-label promotion of INFUSE Bone Graft. The defendants have filed a motion to dismiss, which has been set for hearing on April 14, 2009. On January 9, 2009, Richard Gulbrandsen filed a similar shareholder derivative action against both the Company and certain of its officers, directors, and employees in Hennepin County District Court in the state of Minnesota, alleging breach of fiduciary duty and other claims arising from the same subject matter as the Markewich putative class action complaint.

In addition, on August 11, 2008, a complaint was filed against the Company and certain directors, officers, and other company personnel in the U.S. District Court for the District of Minnesota, alleging violations of the Employee Retirement Income Security Act arising from the same subject matter as the consolidated class complaint. The complaint was filed on behalf of a putative class of participants in and beneficiaries of the Medtronic Inc. Saving and Investment Plan whose individual accounts hold shares of company stock at any time from February 15, 2007 to November 19, 2007. On December 29, 2008, the plaintiff amended the complaint to add similar allegations relating to alleged off-label promotion of INFUSE Bone Graft and to amend the class to include participants in the plan from February 15, 2007 to December 12, 2008. The defendants have filed a motion to dismiss which has been set for hearing on May 13, 2009.

On December 11, 2008, the Minneapolis Firefighters Relief Association filed a putative class action complaint against the Company and two of its officers in the U.S. District Court for the District of Minnesota, alleging violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. The complaint is brought on behalf of persons or entities who purchased securities of Medtronic from November 19, 2007 through November 17, 2008. The complaint alleges that the defendants made false and misleading public statements concerning the INFUSE bone graft product which artificially inflated Medtronic's stock price during the period.

Edgar Filing: MEDTRONIC INC - Form 10-Q

The Company has not recorded an expense related to damages in connection with these shareholder related matters because any potential loss is not currently probable or reasonably estimable under SFAS No. 5.

Mirowski

Medtronic is a licensee to the RE 38,119 patent (119 Patent) and RE 38,897 patent (897 Patent) owned by Mirowski Family Ventures, LLC (Mirowski) relating to the treatment of hemodynamic dysfunction. Medtronic and Mirowski dispute the application of the 119 and 897 Patents to certain Medtronic cardiac resynchronization products. The parties entered into a tolling agreement deferring and conditioning any litigation of the dispute upon conditions precedent. The tolling agreement expired on October 1, 2007. In subsequent notices, Mirowski identified certain claims of the two patents that Mirowski asserts Medtronic is using. On December 17, 2007, Medtronic filed an action in U.S. District Court in Delaware seeking a declaration that none of its products infringe any valid claims of either the 119 or 897 Patents. If certain conditions are fulfilled, the 119 and/or 897 Patents are determined to be valid and the Medtronic products are found to infringe the 119 and/or 897 Patents, Medtronic will be obligated to pay royalties to Mirowski based upon sales of certain CRT-D products. As of January 23, 2009, the amount of disputed royalties and interest related to CRT-D products is \$102. This amount has not been accrued because the outcome is not currently probable under SFAS No. 5.

In addition, Medtronic is a licensee to the 4,407,288 Patent (288 Patent) owned by Mirowski relating to ICDs. Until November 2001, Medtronic accrued and paid royalties under the license based on a percentage of ICD sales. Medtronic and Mirowski dispute the application of the 288 Patent to certain Medtronic ICD products. In November 2001, Medtronic ceased paying royalties and entered into an agreement with Mirowski to pay putative royalties into an interest-bearing escrow account through the expiration of the 288 Patent in December of 2003. As of January 23, 2009, the current balance in the interest-bearing escrow account is \$83. The parties also entered into a tolling agreement deferring and conditioning any litigation of the obligation to pay royalties upon certain conditions precedent. If these conditions are fulfilled and the patent determined to be invalid or Medtronic's products found not to infringe, the escrowed funds will be released to Medtronic.

In the normal course of business, the Company periodically enters into agreements that require it to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company's products or the negligence of its personnel or claims alleging that its products infringe third-party patents or other intellectual property. The Company's maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.

Note 19 Segment and Geographic InformationSegment information:

During fiscal year 2008, the Company revised its operating segment reporting to separate the Navigation business from Spinal. For most of fiscal year 2008, Navigation was reported as part of a stand alone segment named Corporate Technologies and New Ventures. In the fourth quarter of fiscal year 2008, the decision was made to include the Navigation business as a component of the Ear, Nose and Throat (ENT) segment, which was renamed Surgical Technologies to reflect the expanding scope and focus of this business. As a result, the Company now functions in seven operating segments, consisting of CRDM, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies, and Physio-Control. The applicable information for the three and nine months ended January 25, 2008 has been reclassified to conform to the current presentation of seven operating segments.

Each of the Company's operating segments have similar economic characteristics, technology, manufacturing processes, customers, distribution and marketing strategies, regulatory environments, and shared infrastructures. Net sales by operating segment are as follows:

	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Cardiac Rhythm Disease Management	\$ 1,169	\$ 1,218	\$ 3,714	\$ 3,601
Spinal	832	808	2,520	2,112
CardioVascular	565	512	1,792	1,488
Neuromodulation	354	320	1,045	930
Diabetes	277	258	818	744
Surgical Technologies	207	195	622	552
Physio-Control	90	94	259	228
Total Net Sales	\$ 3,494	\$ 3,405	\$ 10,770	\$ 9,655

Edgar Filing: MEDTRONIC INC - Form 10-Q

On December 4, 2006, the Company announced its intention to pursue a spin-off of Physio-Control into an independent, publicly traded company. Physio-Control is the Company's wholly-owned subsidiary that offers external defibrillators, emergency response systems, data management solutions and support services used by hospitals and emergency response personnel. However, shortly thereafter, on January 15, 2007, the Company announced a voluntary suspension of U.S. shipments of Physio-Control products manufactured at its facility in Redmond, Washington in order to address quality system issues. In the months following the suspension of U.S. shipments, the Company worked diligently with the FDA to address the quality system issues and resumed limited shipments to critical customers. As a result of the work performed, on April 28, 2008, the Company announced that it had reached an agreement on a consent decree with the FDA regarding quality system improvements for its external defibrillator products. The agreement was filed on April 25, 2008 in the U.S. District Court for the Western District of Washington and was approved by the court on May 9, 2008. The agreement addresses issues raised by the FDA during inspections regarding Physio-Control's quality system processes and outlines the actions Physio-Control must take in order to resume unrestricted distribution of its external defibrillators. In fiscal year 2008, Physio-Control had resumed limited shipments to critical need customers in the U.S. Following the resolution of the quality system issues, the Company intends to pursue the spin-off of Physio-Control. Physio-Control's income/(loss) before interest and income taxes for the three and nine months ended January 23, 2009 is \$(3) and \$(20), respectively and for the three and nine months ended January 25, 2008 is \$2 and \$(23), respectively.

Geographic information

Net sales to external customers by geography are as follows:

	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
United States	\$ 2,176	\$ 2,098	\$ 6,621	\$ 6,005
Europe	824	838	2,641	2,294
Asia Pacific	382	346	1,151	1,025
Other Foreign	112	123	357	331
Total Net Sales	\$ 3,494	\$ 3,405	\$ 10,770	\$ 9,655

Note 20 Subsequent Events

On February 6, 2009, the Company acquired Ablation Frontiers, Inc. (AFI), a privately held company. Under the terms of the agreement announced on January 12, 2009, the transaction includes an initial up-front payment of \$225 plus potential additional payments contingent upon achievement of certain clinical milestones.

AFI develops radiofrequency (RF) ablation solutions for treatment of atrial fibrillation. AFI's system of ablation catheters and RF generator is currently approved in certain markets outside the U.S. AFI will be part of the Company's CRDM segment.

On February 20, 2009, the Company acquired Ventor Technologies, Ltd. (Ventor), a privately held company. The Company acquired Ventor for a payment of \$325.

In addition to the acquisition of AFI and Ventor, on February 23, 2009 the Company announced it had signed a definitive agreement to acquire CoreValve, Inc. (CoreValve), a privately held company. The terms of the CoreValve transaction include an initial upfront payment of \$700 plus additional payments contingent upon achievement of certain milestones. The close of the transaction is contingent upon regulatory approval in certain jurisdictions.

Both Ventor and CoreValve have developed transcatheter heart valve technologies for replacement of the aortic valve. CoreValve's technology received CE mark approval in 2007 and uses a transfemoral approach to delivery of the valve. Ventor's technology is under clinical investigation in Europe and uses a transapical approach to delivery of the valve. Together these acquisitions will be part of the Company's CardioVascular segment.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**UNDERSTANDING OUR FINANCIAL INFORMATION**

The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Medtronic, Inc. (Medtronic or the Company, or we, us, or our). For a full understanding of financial condition and results of operations, you should read this discussion along with management's discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the fiscal year ended April 25, 2008 and in our Quarterly Reports on Form 10-Q for the fiscal periods ended July 25, 2008 and October 24, 2008. In addition, you should read this discussion along with our condensed consolidated financial statements and related Notes thereto as of January 23, 2009.

Financial Trends

Throughout this financial discussion and analysis, you may read about transactions or events that materially contribute to or reduce earnings and materially affect financial trends. We refer to these transactions and events as either special (such as asset impairments), restructuring, certain litigation, and purchased in-process research and development (IPR&D) charges, or certain tax adjustments. These charges, or benefits, result from facts and circumstances that vary in frequency and/or impact to operations. While understanding these charges is important in understanding and evaluating financial trends, other transactions or events may also have a material impact on financial trends. A complete understanding of the special, restructuring, certain litigation, and IPR&D charges and certain tax adjustments is necessary in order to estimate the likelihood that financial trends will continue.

EXECUTIVE LEVEL OVERVIEW

We are the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world. During fiscal year 2008, we revised our operating segment reporting to separate the Navigation business from Spinal. For most of fiscal year 2008, Navigation was reported as part of a stand-alone segment named Corporate Technologies and New Ventures. In the fourth quarter of fiscal year 2008, the decision was made to include the Navigation business as a component of the Ear, Nose and Throat (ENT) segment, which was renamed Surgical Technologies to reflect the expanding scope and focus of this business. As a result, the Company now functions in seven operating segments, consisting of Cardiac Rhythm Disease Management (CRDM), Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies, and Physio-Control. The applicable information for the three and nine months ended January 25, 2008 has been reclassified to conform to the current presentation of seven operating segments.

Through these seven operating segments, we develop, manufacture, and market our medical devices in more than 120 countries worldwide. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose, and throat conditions.

Net earnings for the third quarter of fiscal year 2009 were \$723 million, or \$0.65 per diluted share, as compared to net earnings of \$77 million, or \$0.07 per diluted share for the same period in the prior fiscal year. Net earnings for the three months ended January 23, 2009 include an after-tax IPR&D charge that decreased net earnings by \$72 million. Net earnings for the three months ended January 25, 2008 included after-tax special, certain litigation, and IPR&D charges that decreased net earnings by \$636 million. See further discussion of these charges in the Special, Restructuring, Certain Litigation, and IPR&D Charges section of this management's discussion and analysis. The increase in net earnings for the three months ended January 23, 2009 was driven primarily by an increase in net sales, lower IPR&D, and the lack of special or certain litigation charges in the period.

Net earnings for the nine months ended January 23, 2009 were \$2.041 billion, or \$1.81 per diluted share, as compared to net earnings of \$1.418 billion, or \$1.24 per diluted share for the same period in the prior fiscal year, representing an increase of 44 percent and 46 percent, respectively. Net earnings for the nine months ended January 23, 2009 included after-tax restructuring, certain litigation and IPR&D charges that decreased net earnings by \$325 million. Net earnings for the nine months ended January 25, 2008 included after-tax special, restructuring, certain litigation and IPR&D charges that decreased net earnings by \$672 million. See further discussion of these charges in the Special, Restructuring, Certain Litigation, and IPR&D Charges section of this management's discussion and analysis. The increase in net earnings for the nine months ended January 23, 2009 was driven primarily by an increase in net sales and a decrease in special, certain litigation and IPR&D charges.

The table below illustrates net sales by operating segment for the three and nine months ended January 23, 2009 and January 25, 2008:

(dollars in millions)	Three months ended			Nine months ended		
	January 23, 2009	January 25, 2008	% Change	January 23, 2009	January 25, 2008	% Change
Cardiac Rhythm Disease Management	\$ 1,169	\$ 1,218	(4)%	\$ 3,714	\$ 3,601	3%
Spinal	832	808	3	2,520	2,112	19

Edgar Filing: MEDTRONIC INC - Form 10-Q

CardioVascular	565	512	10	1,792	1,488	20
Neuromodulation	354	320	11	1,045	930	12
Diabetes	277	258	7	818	744	10
Surgical Technologies	207	195	6	622	552	13
Physio-Control	90	94	(4)	259	228	14
Total Net Sales	\$ 3,494	\$ 3,405	3%	\$ 10,770	\$ 9,655	12%

29

Edgar Filing: MEDTRONIC INC - Form 10-Q

Net sales for the three and nine months ended January 23, 2009 were \$3.494 billion and \$10.770 billion, an increase of 3 percent and 12 percent, respectively, from the same periods in the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact of \$(110) million and \$111 million on net sales for the three and nine months ended January 23, 2009, respectively, when compared to the same periods in the prior fiscal year. The net sales increase in the current fiscal year was driven by the addition of Kyphon to our Spinal business, the continued demand for the Endeavor drug eluting stent (Endeavor) in our CardioVascular business, and sales growth in the Neuromodulation, Diabetes and Surgical Technologies businesses. See our discussion in the Net Sales section of this management's discussion and analysis for more information on the results of our significant operating segments.

We remain committed to our mission of developing lifesaving and life enhancing therapies to alleviate pain, restore health and extend life. The diversity and depth of our current product offerings enable us to provide medical therapies to patients worldwide. We work to improve patient access through well planned studies, which show the safety, efficacy, and cost-effectiveness of our therapies, and our alliance with patients, clinicians, regulators and reimbursement agencies. Our investments in research and development, strategic acquisitions, expanded clinical trials and infrastructure provide the foundation for our growth. We are confident in our ability to drive long-term shareholder value using principles of our Mission, our strong product pipelines and continued commitment to innovative research and development.

OTHER MATTERS

On December 4, 2006, we announced our intention to pursue a spin-off of Physio-Control into an independent, publicly traded company. Physio-Control is our wholly-owned subsidiary that offers external defibrillators, emergency response systems, data management solutions, and support services used by hospitals and emergency response personnel. However, shortly thereafter, in January 2007, we announced a voluntary suspension of U.S. shipments of Physio-Control products manufactured at our facility in Redmond, Washington in order to address quality system issues. In the months following the suspension of U.S. shipments, we worked diligently with the U.S. Food and Drug Administration (FDA) to address the quality system issues and resumed limited shipments to critical need customers. As a result of the work performed to date, on April 28, 2008, we announced that we had reached an agreement on a consent decree with the FDA regarding quality system improvements for our external defibrillator products. The agreement was filed on April 25, 2008 in the U.S. District Court for the Western District of Washington and was approved by the court on May 9, 2008. The agreement addresses issues raised by the FDA during inspections regarding Physio-Control's quality system processes and outlines the actions Physio-Control must take in order to resume unrestricted distribution of our external defibrillators. We are continuing to work diligently on implementing the required actions necessary to resolve the quality issues addressed by the FDA so that we may resume unrestricted distribution of all products. Following the resolution of the quality system issues, we intend to pursue the spin-off of Physio-Control.

CRITICAL ACCOUNTING ESTIMATES

We have adopted various accounting policies to prepare the condensed consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended April 25, 2008.

The preparation of the condensed consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying Notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, property, plant and equipment, asset impairment, legal proceedings, IPR&D, warranty obligations, product liability, self-insurance, pension and post-retirement obligations, sales returns and discounts, stock-based compensation, valuation of equity and debt securities and income tax reserves are updated as appropriate, which in most cases is quarterly. We base our estimates on historical experience, actuarial valuations or various assumptions that are believed to be reasonable under the circumstances.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

Legal Proceedings

We are involved in a number of legal actions involving both product liability and intellectual property disputes. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, that could require significant expenditures or result in lost revenues. In accordance with Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards (SFAS) No. 5, Accounting for Contingencies, (SFAS No. 5) we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. Our significant legal proceedings are discussed in Note 18 to the condensed consolidated financial statements. While it is not possible to predict the outcome for most of the matters discussed in Note 18 to the condensed consolidated financial statements, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.

Tax Strategies

Our effective tax rate is based on income, statutory tax rates and tax planning opportunities available to us in the various jurisdictions in which we operate. We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. These reserves are established and adjusted in accordance with the principles of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48). Under FIN 48, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. We regularly monitor our tax positions and FIN 48 tax liabilities. We reevaluate the technical merits of our tax positions and recognize an uncertain tax benefit, or derecognize a previously recorded tax benefit, when (i) there is a completion of a tax audit, (ii) there is a change in applicable tax law including a tax case or legislative guidance, or (iii) there is an expiration of the statute of limitations. Significant judgment is required in accounting for tax reserves. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate in future periods.

In the event there is a special, restructuring, certain litigation and/or IPR&D charge recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and recorded. Because the effective rate can be significantly impacted by these discrete items that take place in the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate. The non-GAAP nominal tax rate is defined as the income tax provision as a percentage of earnings before income taxes, excluding special, restructuring, certain litigation, and IPR&D charges. We believe that this resulting non-GAAP financial measure provides useful information to investors because it excludes the effect of these discrete items so that investors can compare our recurring results over multiple periods.

Tax regulations require certain items to be included in the tax return at different times than when those items are required to be recorded in the condensed consolidated financial statements. As a result, our effective tax rate reflected in our condensed consolidated financial statements is different than that reported in our tax returns. Some of these differences are permanent, such as expenses that are not deductible on our tax return, and some are temporary differences, such as depreciation expense. Temporary differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in our tax return in future years for which we have already recorded the tax benefit in our condensed consolidated statements of earnings. We establish valuation allowances for our deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in our condensed consolidated financial statements for which payment has been deferred or expense has already been taken as a deduction on our tax return but has not yet been recognized as an expense in our condensed consolidated statements of earnings.

The Company's overall tax rate including the tax impact of restructuring, certain litigation, and IPR&D charges has resulted in an effective tax rate of 22.44 percent and 19.84 percent for the three and nine months ended January 23, 2009, respectively. Excluding the impact of the restructuring, certain litigation, and IPR&D charges in the three and nine months ended January 23, 2009, our operational and tax strategies have resulted in a non-GAAP nominal tax rate of 20.83 percent and 21.08 percent, respectively, versus the U.S. Federal statutory rate of 35.0 percent. An increase in our nominal tax rate of 1 percent would result in an additional income tax provision for the three and nine months ended January 23, 2009 of approximately \$10 million and \$30 million, respectively. See discussion of the tax rate and the tax adjustments in the Income Taxes section of this management's discussion and analysis.

Valuation of IPR&D, Goodwill, and Other Intangible Assets

When we acquire a company, the purchase price is allocated, as applicable, between IPR&D, other identifiable intangible assets, net tangible assets, and goodwill as required by U.S. GAAP. IPR&D is defined as the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D and other intangible assets requires us to make significant estimates. The amount of the purchase price allocated to IPR&D and other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. For IPR&D, these valuation methodologies include consideration of the risk of the project not achieving commercial feasibility.

Goodwill represents the excess of the aggregate purchase price over the fair value of net assets, including IPR&D, of acquired businesses. Goodwill is tested for impairment annually, or more frequently if changes in circumstance or the occurrence of events suggest that the carrying amount may be impaired.

The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. Our estimates associated with the goodwill impairment tests are considered critical due to the amount of goodwill recorded on our condensed consolidated balance sheets and the judgment required in determining fair value amounts, including projected future cash flows. Goodwill was \$7.744 billion and \$7.519 billion as of January 23, 2009 and April 25, 2008, respectively.

Other intangible assets consist primarily of purchased technology, patents, and trademarks which are amortized using the straight-line or accelerated basis, as appropriate, over their estimated useful lives, ranging from 3 to 20 years. As of January 23, 2009, all of our intangible assets have definite lives and are amortized on a straight-line basis. We review these intangible assets for impairment annually or as changes in circumstance or the occurrence of events suggest the remaining value may not be recoverable. Other intangible assets, net of accumulated amortization, were \$2.186 billion and \$2.193 billion as of January 23, 2009 and April 25, 2008, respectively.

NEW ACCOUNTING PRONOUNCEMENTS

Information regarding new accounting pronouncements is included in Note 2 to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q.

ACQUISITIONS

Three and nine months ended January 23, 2009

On November 12, 2008, we acquired substantially all of the shares of CryoCath Technologies Inc. (CryoCath). Under the terms of the agreement announced on September 25, 2008, CryoCath shareholders received \$8.75 Canadian dollars per share in cash for each share of CryoCath common stock that they owned. Total consideration for the transaction, net of cash acquired, was approximately \$352 million U.S. dollars including the purchase of all outstanding CryoCath common stock, the assumption and settlement of existing CryoCath debt and the payment of direct acquisition costs. CryoCath develops cryotherapy products to treat cardiac arrhythmias. CryoCath's Arctic Front product is a minimally invasive cryo-balloon catheter designed specifically to treat atrial fibrillation and is currently approved in certain markets outside the U.S.

On July 16, 2008, we acquired Restore Medical, Inc. (Restore). Restore's Pillar Palatal Implant System (Pillar System) will be integrated into the Surgical Technologies operating segment. The Pillar System will provide us with a minimally invasive, implantable medical device used to treat the soft palate component of sleep breathing disorders, including mild to moderate obstructive sleep apnea and snoring. Restore shareholders received \$1.60 per share in cash for each share of Restore common stock they owned. Total consideration for the transaction was approximately \$29 million, net of cash acquired.

The pro forma impact of the CryoCath and Restore acquisitions was not significant, individually or in the aggregate, to our results for the three and nine months ended January 23, 2009 or January 25, 2008. The results of operations related to each company have been included in our consolidated statements of earnings since the date each company was acquired.

Three and nine months ended January 25, 2008

On November 2, 2007, we consummated the acquisition of Kyphon and it became our wholly owned subsidiary. Kyphon develops and markets medical devices designed to restore and preserve spinal function using minimally invasive technology. Kyphon's primary products are used in balloon kyphoplasty for the treatment of spinal compression fractures caused by osteoporosis or cancer, and in the interspinous process decompression (IPD) procedure for treating the symptoms of lumbar spinal stenosis. It is expected that the acquisition of Kyphon will add to the growth of our existing Spinal business by extending its product offerings into some of the fastest growing product segments of the spine market, enabling us to provide physicians with a broader range of therapies for use at all stages of the care continuum.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Under the terms of the agreement announced on July 27, 2007, Kyphon shareholders received \$71 per share in cash for each share of Kyphon common stock they owned. Total consideration for the transaction was \$4.203 billion which includes payments to Kyphon shareholders for the cancellation of outstanding shares, the assumption and settlement of existing Kyphon debt, and payment of direct acquisition costs. Total debt assumed relates to Kyphon's obligations under existing credit and term loan facilities and outstanding senior convertible notes. As of the date of the transaction, the existing credit and term loan facilities were fully paid and terminated. The senior convertible notes were converted by the holders in the weeks following the close of the transaction and have been included in the total purchase consideration above. In addition, the total consideration includes the estimated proceeds of unwinding the related convertible note hedges and cancellation and payment of the warrants to the hedge participants that were originally issued by Kyphon in February 2007.

The transaction was financed through a combination of \$3.303 billion cash on hand, the issuance of \$600 million short-term commercial paper and borrowing \$300 million through a new long-term unsecured revolving credit facility.

The results of operations related to Kyphon have been included in our condensed consolidated statements of earnings since the date of the acquisition and include the full amortization of a \$34 million inventory write-up recorded as part of the Kyphon acquisition accounting. The pro forma impact of Kyphon was significant to our results for the three and nine months ended January 25, 2008. See Note 3 to the condensed consolidated financial statements for the unaudited pro forma results of operations for the nine months ended January 25, 2008.

On November 1, 2007, we recorded an IPR&D charge of \$20 million related to the acquisition of Setagon, Inc. (Setagon), a development stage company focused on commercially developing metallic nanoporous surface modification technology. The acquisition will provide us with exclusive rights to use and develop Setagon's Controllable Elution Systems (CES) technology in the treatment of cardiovascular disease. Total consideration for Setagon was approximately \$20 million in cash, subject to purchase price increases, which would be triggered by the achievement of certain milestones.

On June 25, 2007, we acquired substantially all of the O-arm Imaging System (O-arm) assets of Breakaway Imaging, LLC (Breakaway), a privately held company based in Littleton, Massachusetts. Prior to the acquisition, we had the exclusive rights to distribute and market the O-arm. The O-arm provides multi-dimensional surgical imaging for use in spinal and orthopedic surgical procedures. The acquisition is expected to bring the O-arm into a broad portfolio of image guided surgical solutions. Total consideration for Breakaway was approximately \$26 million in cash, subject to purchase price increases, which would be triggered by the achievement of certain milestones. The pro forma impact of Breakaway was not significant to our results for the three and nine months ended January 25, 2008.

In addition to the acquisitions disclosed above, we periodically acquire certain tangible or intangible assets in transactions that do not otherwise warrant separate disclosure. These transactions are largely reflected in the condensed consolidated statements of cash flows as a component of investing activities under *purchase of intellectual property*.

Subsequent Acquisitions

On February 6, 2009, we acquired Ablation Frontiers, Inc. (AFI), a privately held company. Under the terms of the agreement announced on January 12, 2009, the transaction includes an initial up-front payment of \$225 million plus potential additional payments contingent upon achievement of certain clinical milestones. AFI develops radiofrequency (RF) ablation solutions for treatment of atrial fibrillation. AFI's system of ablation catheters and RF generator is currently approved in certain markets outside the U.S. AFI will be part of our CRDM segment.

On February 20, 2009, we acquired Ventor Technologies, Ltd. (Ventor), a privately held company. We acquired Ventor for a payment of \$325.

In addition to the acquisition of AFI and Ventor, on February 23, 2009 it was announced that we had signed a definitive agreement to acquire CoreValve, Inc. (CoreValve), a privately held company. The terms of the CoreValve transaction include an initial upfront payment of \$700 plus additional payments contingent upon achievement of certain milestones. The close of the transaction is contingent upon regulatory approval in certain jurisdictions.

Both Ventor and CoreValve have developed transcatheter heart valve technologies for replacement of the aortic valve. CoreValve's technology received CE mark approval in 2007 and uses a transfemoral approach to delivery of the valve. Ventor's technology is under clinical investigation in Europe and uses a transapical approach to delivery of the valve. Together these acquisitions will be part of our CardioVascular segment.

NET SALES

The table below illustrates net sales by operating segment for the three and nine months ended January 23, 2009 and January 25, 2008:

(dollars in millions)	Three months ended			Nine months ended		
	January 23, 2009	January 25, 2008	% Change	January 23, 2009	January 25, 2008	% Change
Pacing Systems	\$ 457	\$ 478	(4)%	\$ 1,490	\$ 1,468	1%
Defibrillation Systems	694	726	(4)	2,182	2,091	4
Other	18	14	29	42	42	
CARDIAC RHYTHM DISEASE MANAGEMENT	1,169	1,218	(4)	3,714	3,601	3
Core Spine	479	455	5	1,441	1,371	5
Biologics	205	206		624	594	5
Kyphon	148	147	1	455	147	210
SPINAL	832	808	3	2,520	2,112	19
Coronary Stents	186	157	18	630	459	37
Other Coronary/Peripheral	110	103	7	330	294	12
Endovascular	99	70	41	281	208	35
Revascularization and Surgical Therapies	103	109	(6)	332	316	5
Structural Heart Disease	67	73	(8)	219	211	4
CARDIOVASCULAR	565	512	10	1,792	1,488	20
Neuro Implantables	283	260	9	837	760	10
Gastroenterology & Urology	71	60	18	208	170	22
NEUROMODULATION	354	320	11	1,045	930	12
DIABETES	277	258	7	818	744	10
Core ENT	83	81	2	255	231	10
Neurologic Technologies	78	73	7	238	216	10
Navigation	46	41	12	129	105	23
SURGICAL TECHNOLOGIES	207	195	6	622	552	13
PHYSIO-CONTROL	90	94	(4)	259	228	14
TOTAL	\$ 3,494	\$ 3,405	3%	\$ 10,770	\$ 9,655	12%

Net sales for the three and nine months ended January 23, 2009 were (unfavorably)/favorably impacted by foreign currency translation of \$(110) million and \$111 million, respectively, when compared to the same periods of the prior fiscal year. The primary exchange rate movements that impacted our consolidated net sales growth were the U.S. dollar as compared to the Euro and the Japanese Yen. The impact of foreign currency fluctuations on net sales was not indicative of the impact on net earnings due to the offsetting foreign currency impact on operating costs and expenses and our hedging activities. See Item 3 Quantitative and Qualitative Disclosures About Market Risk in this Quarterly Report on Form 10-Q and Note 8 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended April 25, 2008 for further details on foreign currency instruments and our related risk management strategies.

Forward-looking statements are subject to risk factors (see Cautionary Factors That May Affect Future Results set forth in our Annual Report on Form 10-K for the year ended April 25, 2008).

Cardiac Rhythm Disease Management

CRDM products consist primarily of pacemakers, implantable defibrillators, leads, ablation products, electrophysiology catheters, and information systems for the management of patients with our devices. CRDM net sales for the three and nine months ended January 23, 2009 were \$1.169 billion and \$3.714 billion, a decrease of 4 percent and an increase of 3 percent, respectively, when compared to the same periods of the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact on net sales for the three and nine months ended January 23, 2009 of approximately \$(38) million and \$56 million when compared to the same periods of the prior fiscal year.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Worldwide net sales of Defibrillation Systems, our largest product line, for the three and nine months ended January 23, 2009 were \$694 million and \$2.182 billion, a decrease of 4 percent and an increase of 4 percent, respectively, when compared to the same periods of the prior fiscal year. The decrease in net sales for the three months ended January 23, 2009 was primarily a result of a decrease in net sales in the U.S. due to significant competition and an unfavorable impact from foreign currency translation on sales outside the U.S. Net sales growth for the nine months ended January 23, 2009 was primarily a result of net sales growth outside the U.S., specifically from Secura implantable cardioverter defibrillators (ICDs) and Consulta cardiac resynchronization therapy-defibrillators (CRT-Ds), both of which are included within our new Vision 3D portfolio, and the benefit of foreign currency translation. Both the Secura ICDs and Consulta CRT-Ds feature Conexus wireless technology which allows for remote transfer of patient data and enables easier communication between the implanted device and programmer at the time of implant, during follow-up in a clinician's office, or remotely using a patient home monitor. In addition, net sales for the comparative nine months ended January 25, 2008 were negatively impacted by our voluntary suspension of worldwide distribution of Fidelis leads in the second quarter of fiscal year 2008.

Pacing Systems net sales for the three and nine months ended January 23, 2009 were \$457 million and \$1.490 billion, a decrease of 4 percent and an increase of 1 percent, respectively, when compared to the same periods of the prior fiscal year. The decrease in net sales for the three months ended January 23, 2009 was primarily a result of a decrease in net sales in the U.S. due to significant competition and an unfavorable impact from foreign currency translation on sales outside the U.S. Net sales growth for the nine months ended January 23, 2009 was primarily a result of net sales growth outside the U.S. and the benefit of foreign currency translation. Sales outside the U.S. were led by the acceptance of the Adapta family of pacemakers, including the Adapta, Versa, and Sensia models. The Adapta family of pacemakers incorporates an array of automatic features to help physicians improve pacing therapy and streamline the patient follow-up process, potentially minimizing the amount of time spent in a physician's office. Adapta offers Managed Ventricular Pacing, or MVP, which is an atrial based pacing mode that significantly reduces unnecessary pacing in the right ventricle while providing the safety of a dual chamber backup if necessary. Clinical studies have suggested that reducing this unnecessary pacing in the right ventricle may decrease the risk of developing heart failure and atrial fibrillation, a potentially life-threatening irregular heartbeat.

Looking ahead, we expect our CRDM operating segment should be impacted by the following:

The further launch and acceptance of our new Vision 3D portfolio, which represents a common technology platform comprised of a full line of ICDs, CRT-Ds, pacemakers and cardiac resynchronization therapy-pacemakers (CRT-Ps) to address the needs of patients with arrhythmias, heart failure and those at risk of sudden cardiac arrest. The Secura ICD and the Consulta CRT-D, the portfolio's first ICD and CRT-D devices, became commercially available in the U.S. in the second quarter of fiscal year 2009. The Secura ICD and the Consulta CRT-D were commercially available in Western Europe beginning in the first quarter of fiscal year 2009. We expect to launch the Secura ICD and the Consulta CRT-D in Japan in the fourth quarter of fiscal year 2009. The devices within the Vision 3D portfolio provide enhanced follow-up and automaticity features and create meaningful manufacturing synergies. We will continue to develop our industry leading product portfolio to meet the medical needs of our patients.

Physician reimbursement in the U.S. for OptiVol Fluid Status Monitoring, which became effective January 1, 2009. OptiVol Fluid Status Monitoring is found on certain Medtronic CRT-Ds and ICDs and uses low electrical pulses that travel across the thoracic cavity to measure the level of resistance, indicating fluid in the chest which is a common symptom of heart failure. OptiVol's ability to measure fluid status trends over time can provide important insights that are used in conjunction with ongoing monitoring of other patient symptoms.

The recent launch of the EnRhythm MRI SureScan pacing system (EnRhythm MRI) in certain European countries. EnRhythm MRI is the first pacemaker system to be developed and tested specifically for safe use in magnetic resonance imaging (MRI) machines under specified scanning conditions. EnRhythm MRI is designed to address and mitigate interactions between the pacing system and the magnetic resonance environment. EnRhythm MRI became available in select European countries in November 2008. We expect to launch EnRhythm MRI in the U.S. in fiscal year 2010.

The recent U.S. launch of the Reveal XT Insertable Cardiac Monitor (ICM) which offers comprehensive remote monitoring capabilities, via the Medtronic CareLink Network, and which allows physicians to confirm or rule out an abnormal heart rhythm. The Reveal XT ICM became commercially available in the U.S. in February 2009.

Our recent investments in two novel atrial fibrillation technology platforms. During the third quarter of fiscal year 2009, we acquired CryoCath, a medical technology company that develops cryotherapy products to treat cardiac arrhythmias. CryoCath's Arctic Front product is a minimally invasive cryo-balloon catheter designed specifically to treat atrial fibrillation and is currently approved in certain markets outside the U.S. See Note 3 to the condensed consolidated financial statements for additional information. In addition, on February 6, 2009, we acquired AFI, a privately held company that develops RF ablation solutions for treatment of atrial fibrillation. AFI's system of ablation catheters and RF generator is currently approved in certain markets outside the U.S. See Note 20 to the condensed consolidated financial statements for additional information.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Our ability to grow consistently with the market. Our growth in CRDM has been and will continue to be contingent upon continued market growth and our ability to increase our market position. The CRDM market is characterized by significant competition, and in the current market, we believe that Medtronic's growth has been slightly slower than that of the overall market.

Spinal

Spinal products include thoracolumbar, cervical and interbody spinal devices, and bone graft substitutes. Spinal net sales for the three and nine months ended January 23, 2009 were \$832 million and \$2.520 billion, an increase of 3 percent and 19 percent, respectively, over the same periods of the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact on net sales for the three and nine months ended January 23, 2009 of approximately \$(11) million and \$11 million when compared to the same periods of the prior fiscal year. The growth in the nine months ended January 23, 2009 was driven by the third quarter fiscal year 2008 acquisition of Kyphon, which generated revenue of \$455 million and \$147 million in the nine months ended January 23, 2009 and January 25, 2008, respectively. See below and Note 3 to the condensed consolidated financial statements for further discussion about the acquisition of Kyphon.

Core Spinal net sales for the three and nine months ended January 23, 2009 were \$479 million and \$1.441 billion, respectively, both increases of 5 percent over the same periods of the prior fiscal year. Growth in the periods was primarily based on continued acceptance of our products for the thoracolumbar section of the spine. Thoracolumbar net sales growth for the three and nine months ended January 23, 2009 was driven by net sales of the CD HORIZON LEGACY family of products (CD HORIZON) outside the U.S. and net sales growth of the Lumbar Dynamic platform of products in the U.S. CD HORIZON is designed to provide procedural solutions for degenerative, deformity, or trauma applications using color coded implants, unique minimally invasive instruments and ergonomic designs. The growth of our Lumbar Dynamic platform of products, which allows some range in motion as compared to our fixed stabilization devices, was driven by demand for our CD HORIZON LEGACY PEEK Rod System in the U.S. Net sales growth in the U.S. was also driven by net sales of our MAST family of products, which includes a comprehensive offering of minimal-access procedural solutions. Although U.S. net sales in Core Spinal increased over the same periods of the prior fiscal year, the growth was less than the overall U.S. market growth. Our market share in the Core Spinal business continues to experience pressure from the proliferation of smaller, privately held companies competing in this market. In addition, Core Spinal net sales growth for both the three and nine months ended January 23, 2009 was positively impacted from our joint venture with Shandong Weigao Group Medical Polymer Company Limited (Weigao). The joint venture entity, which distributes Medtronic's spinal products and Weigao's orthopedic products in China, commenced operations in September 2008.

Spinal Biologics net sales for the three and nine months ended January 23, 2009 were \$205 million and \$624 million, respectively. Net sales for the three months ended January 23, 2009 were flat in comparison to the same period of the prior fiscal year, whereas net sales for the nine months ended January 23, 2009 increased 5 percent over the same period of the prior fiscal year. For both the three months ended October 24, 2008 and January 23, 2009, we believe growth was negatively impacted by several external factors including, a public health notice from the FDA regarding the off-label use of recombinant human bone morphogenetic protein in the cervical spine that was issued in July 2008, a previously disclosed government investigation, negative newspaper stories, and a whistleblower lawsuit filed against a number of spine surgeons and distributors of INFUSE bone graft. The increase in net sales for the nine months ended January 23, 2009 was driven from net sales in the three months ended July 25, 2008. INFUSE Bone Graft contains a recombinant human bone morphogenetic protein, or rhBMP-2, that induces the body to grow its own bone, eliminating the need for a painful second surgery to harvest bone from elsewhere in the body.

Kyphon net sales for the three and nine months ended January 23, 2009 were \$148 million and \$455 million, an increase of 1 percent and 210 percent, respectively, when compared to the same periods of the prior fiscal year. Kyphon was acquired in the third quarter of fiscal year 2008 and therefore net sales for the comparative nine months ended January 25, 2008 only includes three months of net sales. Kyphon net sales were driven primarily by continued acceptance of balloon kyphoplasty procedures for treating vertebral compression fractures in the U.S. Balloon kyphoplasty, using Kyphon instruments, is presently used primarily by spine specialists, including orthopedic surgeons and neurosurgeons, interventional radiologists and interventional neuroradiologists, who repair compression fractures of the spine caused by osteoporosis, cancer or benign lesions, or trauma, through minimally invasive spine surgeries.

Looking ahead, we expect our Spinal operating segment should be impacted by the following:

Continued acceptance of our products for stabilization of the thoracolumbar section of the spine, including the CD HORIZON LEGACY 5.5 and PEEK 6.35 Rod Systems.

Increased presence outside the U.S. as a result of our joint venture with Weigao to distribute Medtronic's spinal products and Weigao's orthopedic products in China.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Continued regulatory scrutiny of off-label use in medical devices. During the nine months ended January 23, 2009, the FDA issued a public health notice regarding use of bone morphogenetic protein in cervical procedures, which was received negatively by both physicians and payors. As a result, sales of our INFUSE Bone Graft remained flat in comparison to the same period in the prior year. It is uncertain if this trend will continue in subsequent quarters.

CardioVascular

CardioVascular products consist of coronary and peripheral stents and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, tissue ablation systems, and open heart and coronary bypass grafting surgical products. CardioVascular net sales for the three and nine months ended January 23, 2009 were \$565 million and \$1.792 billion, an increase of 10 percent and 20 percent, respectively, over the same periods of the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact on net sales for the three and nine months ended January 23, 2009 of approximately \$(27) million and \$27 million, respectively, when compared to the same periods of the prior fiscal year.

Coronary Stent and Other Coronary/Peripheral net sales for the three and nine months ended January 23, 2009 were \$296 million and \$960 million, an increase of 14 percent and 27 percent, respectively, as compared to the same periods in the prior fiscal year. The increase in net sales for the three and nine months ended January 23, 2009 was primarily the result of the launch of Endeavor in the U.S. which began in the fourth quarter of fiscal year 2008. We had drug-eluting stents commercially available in all global markets except Japan during the nine months ended January 23, 2009. Endeavor and Endeavor Resolute drug-eluting stents generated worldwide revenue of \$126 million and \$453 million for the three and nine months ended January 23, 2009, respectively.

Endovascular net sales for the three and nine months ended January 23, 2009 were \$99 million and \$281 million, an increase of 41 percent and 35 percent, respectively, as compared to the same periods in the prior fiscal year. Net sales in the U.S. for the three and nine months ended January 23, 2009 increased 65 percent and 40 percent, respectively, in comparison to the same periods in the prior fiscal year driven by the U.S. launches of the Talent Abdominal and Thoracic Stent Graft Systems in April 2008 and June 2008, respectively. Net sales outside the U.S. for the three and nine months ended January 23, 2009 increased 23 percent and 29 percent, respectively, in comparison to the same periods in the prior fiscal year driven by the recent launch of our next generation Endurant Abdominal Stent Graft System. The Endurant Abdominal Stent Graft System expands the applicability of endovascular aortic repair to more patients with abdominal aortic aneurysms (AAA) by addressing those AAA patients whose aortas are highly angulated or whose aneurysms have short necks.

Revascularization and Surgical Therapies net sales for the three and nine months ended January 23, 2009 were \$103 million and \$332 million, a decrease of 6 percent and an increase of 5 percent, respectively, as compared to the same periods in the prior fiscal year. The decrease in the three months ended January 23, 2009 is due to a decline in the sales of our cardiopulmonary products outside the U.S. due to increased competition and sales price pressure. The increase for the nine months ended January 23, 2009 was primarily the result of growth outside the U.S. associated with sales of our cannulae and beating heart products.

Structural Heart Disease net sales for the three and nine months ended January 23, 2009 were \$67 million and \$219 million, a decrease of 8 percent and an increase of 4 percent, respectively, as compared to the same periods in the prior fiscal year. The decrease in the three months ended January 23, 2009 was due to the entrance of three new competitive tissue valve products into the U.S. market during the past twelve months. The increase in the nine months ended January 23, 2009 was led by net sales growth outside the U.S. which benefited from the return of the Advantage Mechanical Valve to markets outside the U.S. which had been suspended for a portion of the comparable period. Net sales of our atrial fibrillation technologies outside the U.S. also contributed to the increase in sales for the nine months ended January 23, 2009.

Looking ahead, we expect our CardioVascular operating segment should be impacted by the following:

Continued acceptance in the U.S. of angioplasty products on the Rapid Exchange delivery system, including Endeavor Sprint, the Driver and MicroDriver bare-metal stents, and the Sprinter balloon catheter systems. Rapid Exchange is a type of delivery system that is used in angioplasty procedures to treat coronary artery disease; it is a short-, single-wire delivery system that can be used by one operator. The federal court in the Northern District of California ordered that the injunction preventing our access to the Rapid Exchange delivery system be lifted on October 29, 2008. Although supply constraints during the quarter limited the penetration of Rapid Exchange to our full account base, we believe that access to Rapid Exchange and the recent U.S. market launch of the Endeavor Sprint and five other angioplasty products on a rapid exchange delivery system will increase usage of our angioplasty products in the U.S., particularly in light of the recent launch of two new competitive products in that market.

Continued acceptance of Endeavor, which was launched in the U.S. market in February 2008. Endeavor was the first new drug-eluting stent approved for use in the U.S. market in over four years and provides a beneficial safety and efficacy profile for treating patients with coronary artery disease. Additionally, we anticipate receiving regulatory approval and launching Endeavor in Japan in the first half of fiscal year 2010.

Continued acceptance of Endeavor Resolute in markets outside the U.S. Endeavor Resolute combines the proven drug and stent components of Endeavor with Biolinx, a proprietary biocompatible polymer specifically engineered for drug-eluting stent use. Biolinx facilitates the slower absorption of Zotarolimus while providing excellent biocompatibility. The design goal of Endeavor Resolute is enhanced safety and efficacy in the most complex lesions and patients.

Further acceptance of the Talent AAA Stent Graft System in the U.S. market. The Talent AAA Stent Graft System received FDA approval in April 2008 and was launched in the first quarter of fiscal year 2009. Additionally, we anticipate further growth in the U.S. from the continued roll-out of the Talent Thoracic Stent Graft System, which was initially released in the first quarter of fiscal year 2009.

Continued sales growth outside the U.S. with continued acceptance of our next generation Endurant AAA stent graft and Valiant Thoracic Stent Graft System. The Endurant AAA stent graft received CE Mark approval and was commercially launched late in the first quarter of fiscal year 2009.

Neuromodulation

Neuromodulation products consist of therapeutic and diagnostic devices, including implantable neurostimulation systems, implantable drug delivery devices, and urology and gastroenterology products. Neuromodulation net sales for the three and nine months ended January 23, 2009 were \$354 million and \$1.045 billion, an increase of 11 percent and 12 percent, respectively, when compared to the same periods of the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact on net sales for the three and nine months ended January 23, 2009 of approximately \$(9) million and \$9 million, respectively, when compared to the same periods of the prior fiscal year.

Neuro Implantables is comprised of two product lines: Pain Management and Movement Disorders. Net sales from Neuro Implantables for the three and nine months ended January 23, 2009 were \$283 million and \$837 million, an increase of 9 percent and 10 percent, respectively, when compared to the same periods of the prior fiscal year. Although we experienced solid growth in the period, we believe it was weakened by the launch of a competitive product in the period. The growth for the three and nine months ended January 23, 2009 was driven by sales of products in Pain Management including worldwide sales of the the RestoreULTRA neurostimulation system for pain management and sales in the U.S. of our Specify 5-6-5 surgical lead for spinal cord stimulation. RestoreULTRA, which was launched in March 2008, is our next generation rechargeable neurostimulator with advanced programming capabilities and is the thinnest 16-electrode neurostimulator on the market. Movement Disorders revenue for the three and nine months ended January 23, 2009 was driven by worldwide net sales of Activa Deep Brain Stimulation (DBS) Therapy. Activa DBS Therapy is used for the treatment of common movement disorders including Parkinson's disease, essential tremor, and dystonia.

Net sales of Gastroenterology and Urology products for the three and nine months ended January 23, 2009 were \$71 million and \$208 million, an increase of 18 percent and 22 percent, respectively, when compared to the same periods of the prior fiscal year. The growth in Gastroenterology and Urology for the three and nine months ended January 23, 2009 was led by worldwide sales of our InterStim II product.

Looking ahead, we expect our Neuromodulation operating segment should be impacted by the following:

Continued acceptance of RestoreULTRA, our next generation rechargeable neurostimulator. RestoreULTRA also offers an innovative patient programmer that gives patients the ability to customize their pain control.

Continued acceptance of our Activa DBS Therapy for the treatment of common movement disorders. We continue to educate neurologists and the patient population on the benefits that our Activa DBS Therapy offers them. Additionally, we look forward to the anticipated launch of Activa PC and RC in the U.S., our next generation neurostimulators, in the fourth quarter of fiscal year 2009. Activa PC and RC were launched in Europe in January 2009. Activa PC is a primary cell device and Activa RC is the therapy's first rechargeable device.

Continued acceptance of InterStim Therapy for the treatment of overactive bladder and urinary incontinence.

Continued acceptance of InterStim Therapy for the treatment of fecal incontinence outside the U.S., and future launch and acceptance within the U.S. We have submitted a pre-market approval application in the U.S. for InterStim Therapy for the treatment of fecal incontinence and expect approval in early fiscal year 2010.

Diabetes

Diabetes products consist of external insulin pumps and related consumables (together referred to as Durable Pump Systems), and subcutaneous continuous glucose monitoring systems. Diabetes net sales for the three and nine months ended January 23, 2009 were \$277 million and \$818 million, an increase of 7 percent and 10 percent, respectively, when compared to the same periods of the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact on net sales for the three and nine months ended January 23, 2009 of approximately \$(12) million and \$4 million, respectively, when compared to the same periods of the prior fiscal year.

Durable Pump Systems net sales for the three and nine months ended January 23, 2009 were \$243 million and \$727 million, an increase of 3 percent and 6 percent, respectively, when compared to the same periods of the prior fiscal year. In addition to the continued growth by Durable Pump Systems, net sales of Continuous Glucose Monitoring Systems (CGMS) and other accessories for the three and nine months ended January 23, 2009 were \$34 million and \$91 million, an increase of 60 percent and 54 percent, respectively, when compared to the same periods of the prior fiscal year. Growth for each period was driven by strong acceptance of CGMS worldwide and an increase in U.S. sales of glucose test strips.

Looking ahead, we expect our Diabetes operating segment should be impacted by the following:

Continued acceptance from both physicians and patients of the Paradigm REAL-Time sensor-augmented pump system, which integrates continuous glucose monitoring and insulin pump functionality.

Continued acceptance and improved U.S. reimbursement of the CGMS *iPro*, a continuous glucose monitoring-enabled diagnostic tool that provides the physician and patient with unprecedented insight into their blood-sugar levels, which was launched in the U.S. in July 2008.

Continued acceptance and customer preference for Medtronic products due to the alliances with LifeScan, Inc. (Lifescan), a Johnson & Johnson company, and Bayer Diabetes Care (Bayer), a member of the Bayer group, which we announced on August 21, 2007. The alliances reached with Lifescan (for the U.S. market) and Bayer (for markets outside the U.S.) provide for the distribution and marketing of blood glucose meters that communicate with Medtronic's insulin pumps. These alliances provide our customers an integrated solution for managing diabetes, thereby improving the quality of life and ease of use. We launched our co-developed blood glucose meters with Bayer and LifeScan in February 2008 and April 2008, respectively.

Potential slowdown in consumer spending. Given the elective nature of a Diabetes pump for the management of diabetes and the possible high out-of-pocket costs to the consumer, there is potential exposure to macroeconomic pressures which could negatively impact the near-term sales growth within Diabetes.

Surgical Technologies

Surgical Technologies products are used to treat conditions of the ear, nose, and throat, and certain neurological disorders. Additionally, we manufacture and sell image-guided surgery systems. Our portfolio consists of powered tissue-removal systems and other microendoscopy instruments, implantable devices, nerve monitoring systems, disposable fluid-control products, a Ménière's disease therapy device, hydrocephalus shunt devices, external drainage systems, cranial fixation devices, neuroendoscopes, dura repair products, and image-guided surgery systems. Surgical Technologies net sales for the three and nine months ended January 23, 2009 were \$207 million and \$622 million, an increase of 6 percent and 13 percent, respectively, when compared to the same periods of the prior fiscal year. Foreign currency translation had an (unfavorable)/favorable impact on net sales for the three and nine months ended January 23, 2009 of approximately \$(8) million and \$1 million, respectively, when compared to the same periods of the prior fiscal year.

Edgar Filing: MEDTRONIC INC - Form 10-Q

Core ENT net sales for the three and nine months ended January 23, 2009 were \$83 million and \$255 million, an increase of 2 percent and 10 percent, respectively, when compared to the same periods of the prior fiscal year. The increase for the three and nine months ended January 23, 2009 reflected the continued net sales growth of Fusion EM IGS, an advanced image guidance surgery system to facilitate sinus surgeries. Fusion EM IGS is an electromagnetic-based image-guided surgery product that will avoid line of sight constraints of optical systems. In addition, there was strong performance in nerve monitoring and drill disposables.

Neurologic Technologies net sales for the three and nine months ended January 23, 2009 were \$78 million and \$238 million, an increase of 7 percent and 10 percent, respectively, when compared to the same periods of the prior fiscal year. The primary driver of growth for the three and nine months ended January 23, 2009 was worldwide increased sales of disposables associated with high-speed drill systems including the EHS Stylus high-speed powered surgical drill system. Additionally, the Strata valves, used in the treatment of hydrocephalus, also contributed to the revenue growth.

Navigation net sales for the three and nine months ended January 23, 2009 were \$46 million and \$129 million, an increase of 12 percent and 23 percent, respectively, when compared to the same periods of the prior fiscal year. The increase in net sales for the three and nine months ended January 23, 2009 was based on strong worldwide net sales of the O-arm Imaging Systems, a multi-dimensional surgical imaging platform that is optimized for use in spine and orthopedic surgery, and increased worldwide service revenue.

Looking ahead, we expect our Surgical Technologies operating segment should be impacted by the following:

Continued acceptance of our FUSION EM IGS System, which was launched in the U.S. in the third quarter of fiscal year 2008.

Continued adoption of power systems for sinus procedures outside the U.S., as well as continued global adoption of nerve monitoring for ENT and thyroid procedures.

Launch of new products including the Integrated Power Console, Spine Shaver, and the NIM 3.0, a next generation nerve monitoring system.

Continued acceptance of the O-arm Imaging System.

Further integration of Restore's Pillar System for the treatment of sleep breathing disorders. We anticipate the Pillar System will deliver new growth by providing us with a proven office-based procedure in a very fast growing segment of the obstructive sleep apnea market.

Potential slowdown in consumer and hospital spending as a result of the recent economic downturn. Given the elective nature of many of the underlying ENT procedures and the large capital equipment component of the Surgical Technologies businesses, there is potential exposure to macroeconomic pressures which could negatively impact the near-term sales growth within Surgical Technologies.

Continued net sales growth in all operating segments is contingent on our ability to gain further market share, penetrate existing markets, develop new products, improve existing products and develop new markets.

COSTS AND EXPENSES

The following is a summary of major costs and expenses as a percent of net sales:

	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Cost of products sold	24.3%	25.6%	24.0%	25.9%
Research & development	9.6	9.7	9.2	9.6
Selling, general & administrative	36.0	35.4	35.6	35.3
Special charges		2.3		0.8
Restructuring			0.9	0.1
Certain litigation		10.7	2.5	3.8
IPR&D	2.1	9.1	0.8	3.6
Other expense, net	1.4	3.5	3.2	2.6
Interest (income)/expense, net	(0.1)	(0.3)	0.2	(1.2)

Cost of Products Sold

Cost of products sold for the three and nine months ended January 23, 2009, as a percentage of net sales, decreased 1.3 percentage points and 1.9 percentage points, respectively, when compared to the same periods in the prior fiscal year. Cost of products sold as a percentage of net sales in the three months ended January 23, 2009 was positively impacted by 0.3 of a percentage point of favorable manufacturing variances. In addition, cost of products sold as a percentage of net sales in the comparative three months ended January 25, 2008 was negatively impacted by 1.0 percentage point as a result of the \$34 million increase in cost of products sold related to the step-up to fair value of inventory acquired in the acquisition of Kyphon. Cost of products sold as a percentage of net sales in the nine months ended January 23, 2009 was positively impacted by 0.7 of a percentage point of favorable foreign currency adjustments, 0.3 of a percentage point of favorable manufacturing variances, and 0.5 of a percentage point from other product costs. In addition, cost of products sold as a percentage of net sales in the comparative nine months ended January 25, 2008 was negatively impacted by 0.4 of a percentage point as a result of the \$34 million increase in cost of products sold related to the step-up to fair value of inventory acquired in the acquisition of Kyphon.

Research and Development

Consistent with prior periods, we have continued to invest in the future by spending aggressively on research and development efforts. For the three and nine months ended January 23, 2009, research and development spending was \$337 million and \$987 million, or 9.6 percent and 9.2 percent of net sales, respectively. Research and development spending for the three and nine months ended January 25, 2008 was \$329 million and \$927 million, or 9.7 percent and 9.6 percent of net sales, respectively. While our research and development spending for the three and nine months ended January 23, 2009 increased over the prior year in total, as a percentage of net sales it has decreased for both periods. The decrease is primarily the result of a reclassification of \$11 million and \$34 million in certain expenses to selling, general, and administrative expense for the three and nine months ended January 23, 2009, respectively. These expenses would have otherwise been included in research and development in the prior years.

We remain committed to developing technological enhancements and new indications for existing products, and less invasive and new technologies to address unmet medical needs. That commitment leads to our initiation and participation in numerous clinical trials in every fiscal year. Furthermore, we expect our development activities to help reduce patient care costs and the length of hospital stays in the future. In addition to our investment in research and development, we continue to access new technologies in areas served by our existing businesses, as well as in new areas, through acquisitions, licensing agreements, alliances and certain strategic equity investments.

Selling, General and Administrative

Selling, general and administrative expense for the three months ended January 23, 2009, as a percentage of net sales increased by 0.6 of a percentage point to 36.0 percent, as compared to the same period of the prior fiscal year. For the nine months ended January 23, 2009, there was an increase of 0.3 of a percentage point to 35.6 percent, as compared to the same period of the prior fiscal year. For both the three and nine months ended January 23, 2009, the reclassification of certain expenses from research and development (noted above) had a negative impact of 0.3 of a percentage point. In addition, for the three and nine months ended January 23, 2009, foreign exchange had a negative impact of 0.2 and 0.1 of a percentage point, respectively. We continue to drive our initiatives to leverage our cost structure in order to help reduce selling, general, and administrative expense.

Special, Restructuring, Certain Litigation and IPR&D Charges

Special, restructuring, certain litigation, and IPR&D charges for the three and nine months ended January 23, 2009 and January 25, 2008 were as follows:

(dollars in millions)	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Special charges	\$	\$ 78	\$	\$ 78
Restructuring charges			96	14
Certain litigation charges		366	266	366
IPR&D charges	72	310	90	343
Total special, restructuring, certain litigation and IPR&D charges	72	754	452	801
Net tax impact of special, restructuring, certain litigation and IPR&D charges		(118)	(127)	(129)
Total special, restructuring, certain litigation and IPR&D charges, net of tax	\$ 72	\$ 636	\$ 325	\$ 672

Special

During the three and nine months ended January 23, 2009, there were no special charges.

During the three and nine months ended January 25, 2008, we recorded a special charge related to the impairment of intangible assets associated with our benign prostatic hyperplasia, or enlarged prostate, product line purchased in fiscal year 2002. The development of the market, relative to our original assumptions, has changed as a result of the broad acceptance of a new line of drugs to treat the symptoms of an enlarged prostate. After analyzing the estimated future cash flows utilizing this technology, based on the market development, we determined that the carrying value of these intangible assets was impaired and a write down of \$78 million was necessary. See Note 4 to the condensed consolidated financial statements for further discussion of this special charge.

Restructuring

Global Realignment Initiative

In fiscal year 2008, as part of a global realignment initiative, we recorded a restructuring charge which focused on shifting resources to those areas where we have the greatest opportunities for growth and streamlining operations to drive operating leverage. The global realignment initiative impacted most businesses and certain corporate functions. For additional information, see Note 5 to the condensed consolidated financial statements.

As a continuation of the global realignment initiative that began in fiscal year 2008, in the first quarter of fiscal year 2009 we incurred \$96 million of incremental restructuring charges, which consists of employee termination costs of \$91 million and asset write-downs of \$5 million. The majority of the expense recognized in the first quarter of fiscal year 2009 is related to the execution of our global realignment initiative outside the U.S. This includes the realignment and elimination of personnel throughout Europe and the Emerging Markets and the closure of an existing facility in the Netherlands that will be integrated into the U.S. operations. The remainder of the expense is associated with enhanced severance benefits provided to employees identified in the fourth quarter of fiscal year 2008. These incremental costs were not accrued in fiscal year 2008 because the enhanced benefits had not yet been communicated to the impacted employees.

There were no restructuring charges in the second and third quarters of fiscal year 2009.

As of the end of the first quarter of fiscal year 2009, we had identified approximately 900 positions for elimination through both voluntary and involuntary separation. Of the 900 positions identified, 570 have been eliminated as of January 23, 2009. The restructuring initiatives are scheduled to be substantially complete by the end of fiscal year 2009, and are expected to produce annualized operating savings of approximately \$96 million. These savings will arise mostly from reduced compensation expense.

Fiscal Year 2007 Initiative

In fiscal year 2007, we recorded a restructuring charge that was designed to drive manufacturing efficiencies in our CardioVascular business, downsize our Physio-Control business due to our voluntary suspension of U.S. shipments, and rebalance resources within our CRDM business in response to market dynamics. For additional information, see Note 5 to the condensed consolidated financial statements.

As a continuation of our fiscal year 2007 initiatives, in the first quarter of fiscal year 2008 we incurred \$14 million of incremental restructuring charges associated with compensation provided to employees whose employment terminated with the Company in the first quarter of fiscal year 2008. These incremental costs were not accrued in fiscal year 2007 because these benefits had not yet been communicated to the impacted employees. Included in the total \$14 million restructuring charge is \$4 million of incremental defined benefit pension and post-retirement related expense for those employees who accepted early retirement packages. For further discussion on the incremental defined benefit pension and post-retirement related expense, see Note 17 to the condensed consolidated financial statements.

When the restructuring initiative began in fiscal year 2007, we identified approximately 900 positions for elimination which were achieved through early retirement packages offered to employees, voluntary separation, and involuntary separation, as necessary. As of April 25, 2008, the initiatives begun in the fourth quarter of fiscal year 2007 were substantially complete.

Certain Litigation

We classify material litigation reserves recognized as certain litigation charges. During the three months ended January 23, 2009, there were no certain litigation charges. During the nine months ended January 23, 2009, we incurred certain litigation charges of \$266 million. Of the amount recorded, \$229 million relates to litigation with Cordis Corporation (Cordis), a subsidiary of Johnson & Johnson (J&J). The Cordis litigation originated in October 1997 and pertains to patent infringement claims on previous generations of bare metal stents that are no longer on the market. On September 30, 2008, the U.S. District Court entered final judgment including accrued interest, totaling approximately \$521 million, to Cordis. We had previously recorded a charge of \$243 million related to this litigation in the third quarter of fiscal year 2008. At the time the \$243 million charge was recorded, the range of potential loss related to this matter was subject to a high degree of estimation. The amount recorded represented an estimate of the low end of the range of probable outcomes related to the matter. Given that the Company and J&J are involved in a number of litigation matters which span across businesses, we entered into negotiations with J&J in an attempt to settle some of the additional litigation simultaneous with the payment of this judgment. Ultimately, the agreement reached with Cordis required a total cash payment of \$472 million, which included the settlement of several outstanding legal matters between the parties. The charge of \$229 million in the nine months ended January 23, 2009 is the net result of \$472 million in cash payments, offset by the existing reserves on the balance sheet including interest accrued on the \$243 million since the date established. The remainder of the certain litigation charge of \$37 million relates to costs for the settlement of litigation that originated in May 2006 with Fastenetix LLC (Fastenetix), a patent holding company. The agreement reached with Fastenetix required a total cash payment of \$125 million for the settlement of ongoing litigation and the purchase of patents. Of the \$125 million, \$37 million was assigned to past damages in the case and the remaining \$88 million was recorded as purchased intellectual property that has an estimated useful life of 7 years. As of October 24, 2008, all of these amounts had been paid.

During the three and nine months ended January 25, 2008, we incurred certain litigation charges of \$366 million. Of the amount recorded, \$123 million relates to the settlement of certain lawsuits relating to the Marquis line of ICDs and CRT-Ds that were subject to a field action announced on February 10, 2005. The remainder of the charge, \$243 million, relates to an estimated reserve established for litigation with Cordis. In May 2008, we paid substantially all of the settlement for certain lawsuits relating to the Marquis line of ICDs and CRT-Ds.

IPR&D Charges

During the three months ended January 23, 2009, we recorded \$72 million of IPR&D charges related to technology acquired through the purchase of CryoCath that had not yet reached technological feasibility and had no future alternative use.

During the nine months ended January 23, 2009, we recorded \$90 million of IPR&D charges of which \$72 million related to CryoCath and \$18 million related to the purchase of certain intellectual property for use in our Spinal business. These payments were expensed as IPR&D since technological feasibility of the underlying projects had not yet been reached and such technology has no future alternative use. See Note 3 to the condensed consolidated financial statements for further discussion of these IPR&D charges.

During the three months ended January 25, 2008, we recorded \$310 million of IPR&D charges of which \$290 million related to technology acquired through the purchase of Kyphon that had not yet reached technological feasibility and had no future alternative use and \$20 million related to the purchase of intellectual property from Setagon, Inc. that had not yet reached technological feasibility and had no future alternative use.

During the nine months ended January 25, 2008, we recorded \$343 million of IPR&D charges of which \$290 million related to Kyphon, \$20 million related to the purchase of intellectual property from Setagon, Inc., \$25 million related to a milestone payment under the existing terms of a royalty bearing, non-exclusive patent cross-licensing agreement with NeuroPace, Inc., and \$8 million from unrelated purchases of certain intellectual property. These payments were expensed as IPR&D since technological feasibility of the underlying projects had not yet been reached and such technology has no future alternative use. See Note 3 to the condensed consolidated financial statements for further discussion of these IPR&D charges.

Other Expense, Net

Other expense, net includes intellectual property amortization expense, royalty income and expense, realized equity security gains and losses, realized foreign currency transaction and derivative gains and losses and impairment charges on equity securities. Other expense, net for the three and nine months ended January 23, 2009 decreased \$69 million and increased \$96 million, to \$50 million and \$344 million, respectively, compared to the same periods in the prior fiscal year. The decrease of \$69 million for the three months ended January 23, 2009 was primarily due to currency hedges, which resulted in income of \$31 million in the current period compared to losses of \$41 million in the same period of the prior fiscal year, partially offset by incremental expense from Endeavor royalties. The increase of \$96 million for the nine months ended January 23, 2009 was primarily due to currency hedges, which resulted in losses of \$78 million in the current period compared to \$58 million in the same period of the prior fiscal year and \$69 million of amortization on intangible assets related to the Kyphon acquisition in the current period compared to \$23 million in the same period of the prior fiscal year. The current period also included incremental expense from Endeavor royalties.

Interest (Income)/Expense, Net

Interest (income)/expense, net includes interest earned on our investments, interest paid on our borrowings, amortization of debt issuance costs and the net realized gain or loss on the sale or impairment of available-for-sale (AFS) debt securities. For the three and nine months ended January 23, 2009, we had interest (income)/expense, net of \$(2) million and \$17 million, respectively, as compared to interest (income)/expense, net of \$(9) million and \$(114) million for the same periods of the prior fiscal year. The decrease in interest income, net during the three months ended January 23, 2009 is the result of lower interest rates being earned on our short- and long-term investments, and a \$12 million impairment charge recorded on our marketable securities portfolio due to the decline in market conditions during the three months ended January 23, 2009. These decreases were partially offset by net gains on sales of AFS debt securities of \$17 million during the three months ended January 23, 2009. The change from interest income, net of \$114 million in the nine months ended January 25, 2008 to interest expense, net of \$17 million in the nine months ended January 23, 2009, is the result of lower interest rates being earned on our short- and long-term investments, and a \$33 million impairment charge recorded on our marketable securities portfolio due to the decline in market conditions during the nine months ended January 23, 2009. These decreases in interest income were partially offset by net gains on sales of AFS debt securities of \$18 million during the nine months ended January 23, 2009. In addition, interest expense, net for the nine months ended January 23, 2009 was also impacted by the \$3.303 billion of cash used in partially financing the Kyphon acquisition. See our discussion in the Liquidity and Capital Resources section of this management's discussion and analysis for more information regarding our investment portfolio.

INCOME TAXES

(dollars in millions)	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
Provision for Income Taxes	\$ 209	\$ 58	\$ 505	\$ 463
Effective tax rate	22.44%	42.77%	19.84%	24.61%
Impact of special, restructuring, certain litigation, and IPR&D charges	(1.61)	(22.93)	1.24	(2.49)
Non-GAAP nominal tax rate (1)	20.83%	19.84%	21.08%	22.12%

(1) Non-GAAP nominal tax rate is defined as the income tax provision as a percentage of earnings before income taxes, excluding special, restructuring, certain litigation, and IPR&D charges. We believe that the resulting non-GAAP financial measure provides useful information to investors because it excludes the effect of these discrete items so that investors can compare our recurring results over multiple periods.

Our effective tax rate for the three and nine months ended January 23, 2009 was 22.44 percent and 19.84 percent, respectively, compared to 42.77 percent and 24.61 percent, respectively, from the same periods of the prior fiscal year. The change in our effective tax rate was primarily due to the impact of special, restructuring, certain litigation, and IPR&D charges, the impact of tax benefits derived from our international operations, and operational tax benefits discussed below. Our non-GAAP nominal tax rate for the three and nine months ended January 23, 2009 was 20.83 percent and 21.08 percent, respectively, compared to 19.84 percent and 22.12 percent from the same periods of the prior fiscal year. The change in the Company's non-GAAP nominal tax rate for the three and nine months ended January 23, 2009 as compared to the same periods of the prior fiscal year was due to the impact of tax benefits derived from our international operations and operational tax benefits discussed below.

During the three months ended January 23, 2009, we recorded \$12 million in operational tax benefits for the finalization of certain tax returns and changes to uncertain tax position reserves. During the comparative three months ended January 25, 2008, we recorded \$30 million in operational tax benefits for the finalization of certain tax returns and changes to uncertain tax position reserves. Lastly, during the nine months ended January 23, 2009, we also recorded a \$16 million operational tax benefit associated with the retroactive renewal and extension of the research and development credit enacted by the Tax Extenders and Alternative Minimum Tax Relief Act of 2008. The \$16 million tax benefit related to a retroactive adjustment for the first seven months of calendar year 2008. The research and development credit related to subsequent months is included in the rate from the second quarter of fiscal year 2009 and forward. These tax adjustments are operational in nature and are recorded in *provision for income taxes* on the condensed consolidated statements of earnings. Excluding the impact of operational tax adjustments, the Company's non-GAAP nominal tax rate would have been 22.00% for the three and nine months ended January 23, 2009 compared to 23.25% for the same periods of the prior fiscal year. The decrease is primarily due to the income tax benefit derived from our international operations. See Note 13 to the condensed consolidated financial statements for further information.

LIQUIDITY AND CAPITAL RESOURCES

(dollars in millions)	January 23, 2009	April 25, 2008
Working capital	\$ 4,038	\$ 3,787
Current ratio*	2.3:1.0	2.1:1.0
Cash, cash equivalents, and short-term investments	\$ 1,743	\$ 1,613
Long-term investments in debt securities**	2,135	2,078
Cash, cash equivalents, short-term investments, and long-term debt securities	\$ 3,878	\$ 3,691
Short-term borrowings and long-term debt	\$ 6,709	\$ 6,956
Net cash position***	\$ (2,831)	\$ (3,265)

* Current ratio is the ratio of current assets to current liabilities.

** Long-term investments include debt securities with a maturity date greater than one year from the end of the period.

*** Net cash position is the sum of cash, cash equivalents, short-term investments and long-term investments in debt securities less short-term borrowings and long-term debt.

We believe our liquidity remains strong as of January 23, 2009 and our strong balance sheet and liquidity provide us with flexibility in the future. We believe our existing cash and investments, as well as our unused lines of credit and commercial paper capacity of \$2.179 billion, if needed, will satisfy our foreseeable working capital requirements for at least the next twelve months. However, we periodically consider various financing alternatives and may, from time to time, seek to take advantage of favorable interest rate environments or other market conditions. At January 23, 2009, our Standard and Poor's Ratings Group and Moody's Investors Service ratings remain unchanged as compared to the fiscal year ending April 25, 2008 with long-term debt ratings of AA- and A1, respectively, and strong short-term debt ratings of A-1+ and P-1.

The increase in our net cash position in the third quarter of fiscal year 2009 as compared to the fiscal year ending April 25, 2008, was primarily due to income generated from operations offset by cash used for litigation settlements, capital expenditures, dividend payments, share repurchases, the acquisition of CryoCath (see Note 3 to the condensed consolidated financial statements for further information), and the purchase of a 15 percent equity interest in Weigao (see the Summary of Cash Flows section of this management's discussion and analysis).

Subsequent to January 23, 2009, we announced the acquisitions of AFI, Ventor, and CoreValve (see Note 20 to the condensed consolidated financial statements for further information). Based on each transaction's terms, the upfront cash payments required subsequent to the third quarter total \$1.250 billion.

We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, or cash flows. See the Off-Balance Sheet Arrangements and Long-Term Contractual Obligations section of this management's discussion and analysis for further information.

Note 18 to the condensed consolidated financial statements provides information regarding amounts we have accrued, if any, related to significant legal proceedings. In accordance with SFAS No. 5, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. For the nine months ended January 23, 2009, we have made significant payments related to certain legal proceedings. For information regarding these payments, please see the Summary of Cash Flows section of this management's discussion and analysis for further information.

At January 23, 2009 and April 25, 2008, approximately \$3.570 billion and \$3.317 billion, respectively, of cash, cash equivalents, short-term investments and long-term investments in debt securities were held by our non-U.S. subsidiaries. These funds are available for use by worldwide operations; however, if these funds were repatriated to the U.S. or used for U.S. operations, the amounts would generally be subject to U.S. tax. As a result, we have not chosen to repatriate this cash but instead use cash generated from U.S. operations and short- and long-term borrowings to meet our U.S. cash needs. Long-term investments also include \$100 million of cash invested in government securities held in an indemnification trust established for self-insurance coverage for our directors and officers. These investments are restricted and are the property of the trust and can only be used to indemnify or advance expenses related to claims against our directors and/or officers.

Edgar Filing: MEDTRONIC INC - Form 10-Q

The IRS recently issued guidance that expands the ability of a U.S. corporation to obtain financing from its foreign subsidiaries without the financing acting as a deemed repatriation of cash. At January 23, 2009, Medtronic, Inc., our parent corporation, had outstanding borrowings of approximately \$903 million from one of our non-U.S. subsidiaries. The proceeds of this inter-company note were used to reduce short-term borrowings (also reduced cash and short-term investments as of January 23, 2009). Subsequent to the quarter ended January 23, 2009, we repaid this inter-company note to our foreign subsidiary using proceeds from short-term borrowings. None of these borrowings acted as a repatriation of cash to the U.S.

We have investments in marketable debt securities that are classified and accounted for as available-for-sale. Our debt securities include government securities, commercial paper, corporate debt securities, bank certificates of deposit, and mortgage backed and other asset backed securities including auction rate securities. Market conditions during the first three quarters of fiscal year 2009 and subsequent to our January 23, 2009 quarter-end continue to indicate significant uncertainty on the part of investors on the economic outlook for the U.S. and for financial institutions. This uncertainty has created reduced liquidity across the fixed income investment market, including certain securities in which we have invested. As a result, some of our investments have experienced reduced liquidity including unsuccessful monthly auctions for our auction rate security holdings. Although certain securities are illiquid, if we required capital we believe we could liquidate a substantial amount of our portfolio and incur no material impairment loss or borrow under our commercial paper program or lines of credit.

For the three and nine months ended January 23, 2009, we recognized an other-than-temporary impairment loss on AFS debt securities of \$12 million and \$33 million, respectively. In determining this other-than-temporary impairment loss, we considered the guidance provided by SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, and related guidance. This guidance specifies that we consider a variety of factors, including the quality and estimated value of the underlying credit support for our holding and the financial condition and credit rating of the issuer. Based on our assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which we are invested, we believe we have recorded all necessary other-than-temporary impairments as we have the ability and the intent to hold these investments long enough to avoid realizing further losses. However, as of January 23, 2009, we have \$172 million of gross unrealized losses on our aggregate short-term and long-term investments of \$2.595 billion; if market conditions continue to deteriorate further, some of these holdings may experience other-than-temporary impairment in the future which could have a material impact on our financial results. Management is required to use estimates and assumptions in its valuation of our investments, which requires a high degree of judgment, and therefore actual results could differ materially from those estimates. See Note 7 to the condensed consolidated financial statements for additional information regarding fair value measurements under SFAS No. 157, Fair Value Measurements.

SUMMARY OF CASH FLOWS

(dollars in millions)	Nine months ended	
	January 23, 2009	January 25, 2008
Cash provided by (used in):		
Operating activities	\$ 2,755	\$ 2,900
Investing activities	(1,245)	(2,686)
Financing activities	(1,217)	(696)
Effect of exchange rate changes on cash and cash equivalents	(70)	(45)
Net change in cash and cash equivalents	\$ 223	\$ (527)
Operating Activities		

Our net cash provided by operating activities was \$2.755 billion for the nine months ended January 23, 2009 compared to \$2.900 billion provided by operating activities for the nine months ended January 25, 2008. The \$145 million decrease in net cash provided by operating activities was primarily attributable to payments for litigation settlements partially offset by continued increases in cash flows from operations. In the first quarter of fiscal year 2009, we paid substantially all of the \$123 million settlement for certain lawsuits relating to the Marquis line of ICDs and CRT-Ds and we paid the \$75 million settlement for the Kyphon qui tam complaint, which we assumed as a liability in the acquisition of Kyphon. For more information regarding these settlements, refer to Note 15 of the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 25, 2008. In the second quarter of fiscal year 2009, we paid \$472 million in settlement of the Cordis litigation, which pertains to patent infringement claims on previous generations of bare metal stents that are no longer on the market, and paid \$125 million to Fastenetix for the settlement of ongoing litigation and the purchase of patents. Of the \$125 million paid to Fastenetix, \$37 million was assigned to past damages in the case and was therefore recorded as a certain litigation charge in the second quarter of fiscal year 2009. The \$37 million is reflected in our cash flow from operations, while the remaining \$88 million is recorded as purchased intellectual property and included in cash flow from investing activities. Please see the Restructuring, Certain Litigation, and IPR&D Charges section of this management's discussion and analysis for further information.

Investing Activities

Our net cash used in investing activities was \$1.245 billion for the nine months ended January 23, 2009 compared to \$2.686 billion used in investing activities for the nine months ended January 25, 2008. The decrease in cash used for investing activities in the nine months ended January 23, 2009 is primarily related to a decrease in cash used for acquisitions partially offset by net purchases of marketable securities in the current period as compared to net proceeds in the comparable nine months ended January 25, 2008. The large inflow of cash related to the net sales of marketable securities in the nine months ended January 25, 2008 is primarily related to the liquidation of marketable securities in anticipation of the close of the Kyphon acquisition which took place in the third quarter of fiscal year 2008. The \$1.245 billion net cash used in investing activities for the nine months ended January 23, 2009 includes \$352 million, net of cash acquired, used for the acquisition of Cryocath, which was completed on December 18, 2008. See Note 3 for additional information regarding the acquisition of Cryocath. Other investing activities for the nine months ended January 23, 2009 also includes \$221 million of cash used to purchase a 15 percent equity interest in Weigao, which was acquired on December 18, 2008.

Financing Activities

Our net cash used in financing activities was \$1.217 billion for the nine months ended January 23, 2009 compared to \$696 million for the nine months ended January 25, 2008. The \$521 million increase in net cash used in financing activities was primarily attributable to the repayment of short-term and long-term debt that was borrowed in the comparable period and an increase in cash used for dividend payments to shareholders. These cash outflows were partially offset by a decrease in cash used for stock repurchases. The net cash provided by the issuance of short-term debt and long-term debt for the nine months ended January 25, 2008 is primarily due to the acquisition of Kyphon which was consummated on November 2, 2007. The transaction was financed through a combination of \$3.303 billion of cash on hand, the issuance of \$600 million short-term commercial paper and borrowing \$300 million through a long-term unsecured revolving credit facility.

OFF-BALANCE SHEET ARRANGEMENTS AND LONG-TERM CONTRACTUAL OBLIGATIONS

We acquire assets still in development, enter into research and development arrangements and sponsor certain clinical trials that often require milestone and/or royalty payments to a third-party, contingent upon the occurrence of certain future events. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of a product or upon certain pre-designated levels of achievement in clinical trials. In addition, if required by the arrangement, we may have to make royalty payments based on a percentage of sales related to the product under development or in the event that regulatory approval for marketing is obtained. In situations where we have no ability to influence the achievement of the milestone or otherwise avoid the payment, we have included those milestone or minimum royalty payments in the following table. However, the majority of these arrangements give us the discretion to unilaterally make the decision to stop development of a product or cease progress of a clinical trial, which would allow us to avoid making the contingent payments. Although we are unlikely to cease development if a device successfully achieves clinical testing objectives, these payments are not included in the table of contractual obligations because of the contingent nature of these payments and our ability to avoid them if we decided to pursue a different path of development or testing.

In the normal course of business, we periodically enter into agreements that require us to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of our products or the negligence of our personnel or claims alleging that our products infringe third-party patents or other intellectual property. Our maximum exposure under these indemnification provisions cannot be estimated, and we have not accrued any liabilities within our consolidated financial statements or included any indemnification provisions in our commitments table. Historically, we have not experienced significant losses on these types of indemnification obligations.

We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position or cash flows. Presented below is a summary of contractual obligations and other minimum commercial commitments as of January 23, 2009. See Note 8 to the condensed consolidated financial statements for additional information regarding long-term debt. See Note 13 to the condensed consolidated financial statements for additional information regarding accrued income tax obligations, which are not reflected in the table below.

Edgar Filing: MEDTRONIC INC - Form 10-Q

	Total	Remaining 2009	Maturity by Fiscal Year				
			2010	2011	2012	2013	Thereafter
<i>(dollars in millions)</i>							
<i>Contractual obligations related to off-balance sheet arrangements:</i>							
Foreign currency contracts (1)	\$ 6,100	\$ 1,889	\$ 2,461	\$ 1,501	\$ 249	\$	\$
Operating leases (2)	252	39	73	45	26	20	49
Inventory purchases (3)	621	86	259	113	36	33	94
<i>Commitments to fund minority investments/contingent acquisition consideration (4)</i>							
Interest payments (5)	479	57	115	106	64	64	73
Other (6)	222	16	55	46	32	14	59
Total	\$ 7,890	\$ 2,102	\$ 3,013	\$ 1,831	\$ 431	\$ 155	\$ 358
<i>Contractual obligations reflected in the balance sheet:</i>							
Long-term debt, excluding capital leases (7)	\$ 5,415	\$	\$	\$ 2,600	\$ 15	\$ 2,200	\$ 600
Capital leases (8)	67		13	16	17	20	1
Total	\$ 5,482	\$	\$ 13	\$ 2,616	\$ 32	\$ 2,220	\$ 601

- (1) As these obligations were entered into as hedges, the majority of these obligations will be offset by losses/gains on the related assets, liabilities and transactions being hedged.
- (2) Certain leases require us to pay real estate taxes, insurance, maintenance, and other operating expenses associated with the leased premises. These future costs are not included in the schedule above.
- (3) We have included inventory purchase commitments which are legally binding and specify minimum purchase quantities. These purchase commitments do not exceed our projected requirements and are in the normal course of business. These commitments do not include open purchase orders.
- (4) Certain commitments related to the funding of minority investments and/or previous acquisitions are contingent upon the achievement of certain product-related milestones and various other favorable operational conditions. While it is not certain if and/or when these payments will be made, the maturity dates included in this table reflect our best estimates.
- (5) Interest payments in the table above reflect the interest on our outstanding debt, including the \$4.400 billion of Senior Convertible Notes, \$1.000 billion of Senior Notes and \$15 million of Contingent Convertible Debentures. The interest rate on each outstanding obligation varies and interest is payable semi-annually. The interest rate is 1.500 percent on the \$2.200 billion Senior Convertible Notes due 2011 and 1.625 percent on the \$2.200 billion Senior Convertible Notes due 2013, 4.375 percent on the \$400 million of Senior Notes due 2010, 4.750 percent on the \$600 million of Senior Notes due 2015, and 1.250 percent on the Contingent Convertible Debentures due 2021.
- (6) These obligations include certain research and development arrangements.
- (7) Long-term debt in the table above includes \$4.400 billion Senior Convertible Notes issued in April 2006, and \$1.000 billion Senior Notes issued in September 2005 and \$15 million related to our Contingent Convertible Debentures. The table above excludes the remaining fair value from the five year interest rate swap entered into in November 2005 and the eight year interest rate swap agreement entered into in June 2007 that were terminated in December 2008. See Note 8 to the condensed consolidated financial statements for additional information regarding the interest rate swap agreement terminations.
- (8) Capital lease obligations include a sale-leaseback agreement entered into in fiscal year 2006 whereby certain manufacturing equipment was sold and is being leased by us over a seven year period.

DEBT AND CAPITAL

Our capital structure consists of equity and interest-bearing debt. Interest-bearing debt as a percentage of total interest-bearing debt and equity was 34 percent at January 23, 2009 in comparison to 38 percent at April 25, 2008.

Share Repurchase Program

In June 2007, our Board of Directors authorized the repurchase of up to 50 million shares of our common stock. In addition, in April 2006, the Board of Directors made a special authorization for the repurchase of up to 50 million shares in connection with the \$4.400 billion Senior Convertible Note offering.

Shares are repurchased from time to time to support our stock-based compensation programs and to take advantage of favorable market conditions. During the three and nine months ended January 23, 2009, we repurchased approximately 2.6 million and 15.5 million shares, respectively, at an average price per share of \$35.03 and \$46.98, respectively. As of January 23, 2009, we have approximately 18.8 million shares remaining under current buyback authorizations approved by the Board of Directors.

Financing Arrangements

We have used a combination of bank borrowings and commercial paper to fund our short-term needs. Short-term debt, including the current portion of our capital lease obligations, at January 23, 2009 was \$1.184 billion compared to \$1.154 billion at April 25, 2008. We utilize a combination of contingent convertible debentures, senior convertible notes, and senior notes to meet our long-term financing needs. Long-term debt at January 23, 2009 was \$5.525 billion compared to \$5.802 billion at April 25, 2008. For more information on our financing arrangements, see Note 8 to the condensed consolidated financial statements.

Credit Arrangements and Debt Ratings

We have existing unsecured lines of credit of approximately \$2.850 billion with various banks at January 23, 2009. The existing lines of credit include a five-year \$1.750 billion syndicated credit facility dated December 20, 2006 that will expire on December 20, 2011 (Credit Facility). The Credit Facility provides backup funding for the commercial paper program and may also be used for general corporate purposes.

The Credit Facility provides us with the ability to increase its capacity by an additional \$500 million at any time during the life of the five-year term of the agreement.

As of January 23, 2009 and April 25, 2008, we have unused credit lines and commercial paper capacity of approximately \$2.179 billion and \$1.945 billion, respectively.

We maintain a commercial paper program that allows us to have a maximum of \$2.250 billion in commercial paper outstanding, with maturities up to 364 days from the date of issuance. As of January 23, 2009 and April 25, 2008, outstanding commercial paper totaled \$1.011 billion and \$874 million, respectively. During the three and nine months ended January 23, 2009, the weighted average original maturity of the commercial paper outstanding was approximately 65 days and 48 days, respectively, and the weighted average interest rate was 1.49 percent and 1.93 percent, respectively. The issuance of commercial paper reduces the amount of credit available under our existing lines of credit.

In connection with the issuance of the contingent convertible debentures, Senior Notes, Senior Convertible Notes and commercial paper, Standard and Poor's Ratings Group and Moody's Investors Service issued us strong long-term debt ratings of AA- and A1, respectively, and strong short-term debt ratings of A-1+ and P-1, respectively. These ratings remain unchanged as compared to the fiscal year ending April 25, 2008. For more information on credit arrangements, see Note 8 to the condensed consolidated financial statements.

OPERATIONS OUTSIDE OF THE UNITED STATES

The table below illustrates U.S. net sales versus net sales outside the U.S. for the three and nine months ended January 23, 2009 and January 25, 2008:

(dollars in millions)	Three months ended		Nine months ended	
	January 23, 2009	January 25, 2008	January 23, 2009	January 25, 2008
U.S. net sales	\$ 2,176	\$ 2,098	\$ 6,621	\$ 6,005
Non-U.S. net sales	1,318	1,307	4,149	3,650
Total net sales	\$ 3,494	\$ 3,405	\$ 10,770	\$ 9,655

Edgar Filing: MEDTRONIC INC - Form 10-Q

For the three and nine months ended January 23, 2009, consolidated net sales outside the U.S. grew 1 percent and 14 percent, respectively, over the same periods of the prior year. For the three months ended January 23, 2009, growth outside the U.S. was 3 percent lower than net sales growth in the U.S. due to an unfavorable foreign currency translation impact of \$110 million. For the nine months ended January 23, 2009, growth outside the U.S. was 4 percent higher than net sales growth in the U.S. Foreign currency translation had a favorable impact of \$111 million on net sales for the nine months ended January 23, 2009. Overall, for the three and nine months ended January 23, 2009, net sales growth outside of the U.S. was led by the Neuromodulation, Diabetes, and Surgical Technologies businesses. In addition, the acquisition of Kyphon in the third quarter of fiscal year 2008 increased the sales growth outside the U.S. as the comparative nine months ended January 25, 2008 only includes three months of Kyphon net sales.

Net sales outside the U.S. are accompanied by certain financial risks, such as collection of receivables, which typically have longer payment terms. Outstanding receivables from customers outside the U.S. totaled \$1.501 billion at January 23, 2009, or 50 percent, of total outstanding accounts receivable, and \$1.800 billion at April 25, 2008, or 53 percent, of total outstanding accounts receivable.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

Certain statements contained in this Quarterly Report on Form 10-Q and other written and oral statements made from time to time by us do not relate strictly to historical or current facts. As such, they are considered forward-looking statements which provide current expectations or forecasts of future events. Our forward-looking statements generally relate to our growth strategies, financial results, product development, regulatory approvals, competitive strengths, the scope of our intellectual property rights, litigation, mergers and acquisitions, integration of our acquisitions, including Kyphon, divestitures, market acceptance or continued acceptance of our products, accounting estimates, financing activities, ongoing contractual obligations, and sales efforts. Such statements can be identified by the use of terminology such as anticipate, believe, could, estimate, expect, forecast, intend, may, plan, possible, potential, project, should, will and similar words. You should carefully consider forward-looking statements that may be affected by inaccurate assumptions, and understand that such statements involve a variety of risks and uncertainties, known and unknown, including, among others, risks related to competition in the medical device industry, reduction or interruption in our supply, quality problems and price decreases for our products and services, and international operations, as well as those discussed in the section entitled Risk Factors in our Annual Report on Form 10-K for the year ended April 25, 2008. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements, and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements.

We undertake no obligation to update any forward-looking statement, but investors are advised to consult any further disclosures by us in our filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q, and 8-K (if any), in which we may discuss in more detail various important factors that could cause actual results to differ from expected or historical results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Due to the global nature of our operations, we are subject to the exposures that arise from foreign currency exchange rate fluctuations. In a period where the U.S. dollar is strengthening as compared to other currencies, our revenues and expenses denominated in foreign currency are translated into a lower value than they would be in an otherwise constant environment. Based on our experience in the nine months ended January 23, 2009, we expect the fourth quarter of the fiscal year will result in a stronger dollar than in the prior fiscal year. As a result, we would anticipate revenue growth rates, and to a lesser extent, earnings will be negatively affected by these changes in currency exchange rates. We manage these exposures using operational and economic hedges as well as derivative financial instruments. The primary currencies hedged are the Euro and the Japanese Yen.

Our objective in managing exposure to foreign currency fluctuations is to minimize earnings and cash flow volatility associated with foreign exchange rate changes. We enter into various contracts, principally forward contracts that change in value as foreign exchange rates change, to protect the value of existing foreign currency assets, liabilities, net investments, and probable commitments. The gains and losses on these contracts offset changes in the value of the related exposures. It is our policy to enter into foreign currency hedging transactions only to the extent true exposures exist; we do not enter into foreign currency transactions for speculative purposes.

We had foreign exchange derivative contracts outstanding in notional amounts of \$6.101 billion and \$6.613 billion at January 23, 2009 and April 25, 2008, respectively. The fair value of these contracts at January 23, 2009 was \$300 million more than the original contract value. A sensitivity analysis of changes in the fair value of all foreign exchange derivative contracts at January 23, 2009 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, the fair value of these contracts would increase/decrease by \$579 million, respectively. Any gains and losses on the fair value of derivative contracts would be largely offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis. We are also exposed to interest rate changes affecting principally our investments in interest rate sensitive instruments. A sensitivity analysis of the impact on our interest rate sensitive financial instruments of a hypothetical 10 percent change in short-term interest rates compared to interest rates at January 23, 2009 indicates that the fair

value of these instruments would correspondingly change by \$19 million.

Edgar Filing: MEDTRONIC INC - Form 10-Q

We have investments in marketable debt securities that are classified and accounted for as available-for-sale. Our debt securities include government securities, commercial paper, corporate debt securities, bank certificates of deposit, and mortgage backed and other asset backed securities including auction rate securities. For a discussion of current market conditions and the impact on Medtronic, please see the Liquidity and Capital Resources section of management's discussion and analysis.

We historically lent certain fixed income securities to enhance our investment income. These lending activities were indemnified against counterparty risk and collateralized at an average rate of 102 percent, with the collateral determined based on the underlying securities and creditworthiness of the borrowers. The value of the securities on loan at April 25, 2008 was \$610 million. Due to our concerns about the liquidity condition in the fixed income markets, we suspended our lending program in the second quarter of fiscal year 2009 and had no lending activity during the third quarter of fiscal year 2009.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)) and changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective and are adequately designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in applicable rules and forms.

Changes in internal control

There have been no changes in the Company's internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

A discussion of the Company's policies with respect to legal proceedings is discussed in the management's discussion and analysis and our legal proceedings and other loss contingencies are described in Note 18 of the condensed consolidated financial statements. The description of our legal proceedings in Note 18 of the condensed consolidated financial statements to this filing is incorporated herein by reference.

On October 24, 2005, the Company received a subpoena from the Office of the United States Attorney for the District of Massachusetts issued under the Health Insurance Portability & Accountability Act of 1996 requesting documents the Company may have, if any, relating to pacemakers and defibrillators and related components; monitoring equipment and services; a provision of benefits, if any, to persons in a position to recommend purchases of such devices; and the Company's training and compliance materials relating to the fraud and abuse and federal Anti-Kickback statutes. In September 2008, the United States Attorney's office for the District of Massachusetts informed Medtronic that it is no longer pursuing its investigation of Medtronic, related to the October 24, 2005 subpoena. On September 5, 2008, Medtronic received a subpoena from the Office of Inspector General for the Department of Health and Human Services in the District of Minnesota, requesting production of substantially the same materials covered in the 2005 Massachusetts subpoena. Medtronic is in the process of responding to the subpoena and will comply as required with the terms of the subpoena.

Beginning on September 20, 2007, the Company has received letter requests from Senator Grassley of the U.S. Senate Finance Committee requesting information on a variety of subjects, including financial ties between the medical device industry and practicing physicians; the Company's decision to suspend distribution of its Sprint Fidelis family of defibrillation leads; financial ties between the Company and physicians who use INFUSE Bone Graft; the Cardiac Research Foundation and Columbia University; and certain communications regarding INFUSE Bone Graft. The Company has cooperated, and will continue to cooperate with, the Senator's requests.

Edgar Filing: MEDTRONIC INC - Form 10-Q

On September 25, 2007, the Company received a letter from the SEC requesting information relating to any potential violations of the U.S. Foreign Corrupt Practices Act in connection with the sale of medical devices in an unspecified number of foreign countries, including Greece, Poland and Germany. Turkey, Italy and Malaysia have since been added to the inquiry. The letter notes that the Company is a significant participant in the medical device industry, and seeks any information concerning certain types of payments made directly or indirectly to government-employed doctors. A number of competitors have publicly disclosed receiving similar letters. On November 16, 2007, the Company received a letter from the Department of Justice requesting any information provided to the SEC. Since that time the SEC and Department of Justice have made additional requests for information from the Company. The Company is cooperating with the requests.

On or about October 31, 2007, the Company received a letter from the United States Attorney's Office for the Eastern District of Pennsylvania requesting documents relating to the Company's relationship with one of its customers and any payments or things of value provided by the Company to physicians, physician groups, hospitals, medical practices or other entities relating to the purchase of the Company's cardiac resynchronization therapy devices and cardiac stents. The Company will comply as required with the terms of the letter.

In late June 2008, the Company received a subpoena issued by the United States Attorney's Office for the District of Massachusetts pursuant to the Health Insurance Portability & Accountability Act of 1996, relating to the Company's marketing of biliary stents. Medtronic will comply as required with the terms of the subpoena.

On October 6, 2008, Medtronic received a subpoena from the United States Attorney's Office for the District of Massachusetts pursuant to the Health Insurance Portability & Accountability Act of 1996 requesting production of documents relating to Medtronic's INFUSE Bone Graft product. Medtronic will comply as required with the terms of the subpoena.

On December 18, 2008, Medtronic received a civil investigative demand from the Massachusetts Attorney General's Office, requesting production of documents related to Medtronic's INFUSE Bone Graft product. Medtronic is in the process of responding to the demand and will comply as required with the terms of the demand.

On February 9, 2009, the Company received letter notice that the United States Department of Justice in the Southern District of Texas is investigating marketing practices, reimbursement advice of the Company and appropriateness of therapy delivery relating to the Company's cardiac surgical ablation devices. The Company is in the process of responding to the requests of the government, and will comply as required with the investigation.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

The following table provides information about the shares repurchased by Medtronic during the third quarter of fiscal year 2009:

Fiscal Period	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as a Part of Publicly Announced Program	Maximum Number of Shares that May Yet Be Purchased Under the Program
10/25/08-11/21/08	2,568,300	\$ 35.03	2,568,300	18,838,084
11/22/08-12/26/08				18,838,084
12/27/08-1/23/09				18,838,084
Total	2,568,300	\$ 35.03	2,568,300	18,838,084

(1) In June 2007, our Board of Directors authorized the repurchase of up to 50 million shares of our common stock. In addition, in April 2006, the Board of Directors made a special authorization for the repurchase of up to 50 million shares in connection with the \$4.400 billion Senior Convertible Note offering. As authorized by the Board of Directors, each program expires when its total number of authorized shares has been repurchased.

Item 6. Exhibits

(a) Exhibits

- 3.1 Medtronic Restated Articles of Incorporation, as amended (Exhibit 3.1)(a).
- 10.1 Form of Amendment to Change of Control Employment Agreement for Medtronic Executive Officers.
- 12.1 Medtronic, Inc. Computation of Ratio of Earnings to Fixed Charges.
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(a) Incorporated herein by reference to the cited exhibit in our Quarterly Report on Form 10-Q for the quarter ended July 27, 2007, filed with the Commission on September 5, 2007.

Edgar Filing: MEDTRONIC INC - Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 4, 2009

Medtronic, Inc.
(Registrant)

/s/ William A. Hawkins
William A. Hawkins
Chairman and Chief Executive Officer

Date: March 4, 2009

/s/ Gary L. Ellis
Gary L. Ellis
Senior Vice President and
Chief Financial Officer